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1. BACKGROUND 
Economic evaluation is used to inform decisions related to setting priorities in health care and 
whether health care interventions should be reimbursed by combining information on costs with 
benefits. The key focus when assessing the benefits from health care interventions is health which 
may be assessed in natural units such as life years saved or quality adjusted life years (QALY) for use 
in cost effectiveness and cost utility analysis respectively. QALYs focus on the health related quality 
of life (HRQoL) associated with different health states which are valued by members of the general 
public.  Costs are the direct costs of providing health care but indirect costs (not funded directly 
through the health care system), which result from having poor health may also be included.  
Indirect costs include productivity losses which refer to costs associated with time off paid and 
unpaid work due to illness. 
 
Measuring the productivity losses associated with specific health conditions has typically focused on 
self-reported or objective data on time off work (Zhang et al.2011).  A different approach relies on 
estimating productivity directly from the health states.  This allows productivity losses associated 
with different health states to be predicted where this information is not available.  In order to 
assess the relationship between productivity and health, patient datasets containing information on 
health related quality of life (HRQoL) on a wide range of conditions measured using accepted HRQoL 
measures (such as EQ-5D) alongside productivity information are required.  This would allow 
productivity losses, for example days off work, to be linked to particular health states described by 
these HRQoL measures.  In addition to patient data, the recall period for the HRQoL measures 
should match the recall period of the productivity losses to minimise bias associated with mismatch 
due to different recall periods.  For example, the recall period in the EQ-5D is today whereas 
measures of productivity such as the Health and Labour Questionnaire (van Roijen et al.1996) use a 
two-week recall period.  Larger studies focusing on productivity tend to ask respondents to consider 
longer periods such as four weeks, three (six or twelve) months (Zhang et al.2011).  Linking longer 
productivity losses to current HRQoL may either overestimate or underestimate the effect of 
conditions.  
 
This aggregate approach of estimating productivity has been used by Krol et al.(2013) using Dutch 
general public data, and Rowen et al.(2013) using UK patient data.  Krol et al.(2013) used the EQ-5D 
and hypothetical time off work estimated by the respondents to develop their model.  Rowen et 
al.(2013) used EQ-5D, International Classification of Diseases (ICD 10) codes and self-reported days 
of work to develop models to predict productivity losses.  Models from Rowen et al.(2013) are 
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applicable in the UK setting as they use the recommended heatlh technology assessment measure, 
the EQ-5D, and have clinical diagnosis data based on ICD which is used by the Department of Health 
in the UK. However, Rowen et al.(2013) identified a number of limitations which may limit 
applicability of their research. 
 
The patient dataset that was used represents individuals who had recently been hospitalised and on 
average, these patients are likely to be sicker than the typical patient treated by the National Health 
Service (NHS) in the UK.  Sicker respondents are likely to have higher productivity losses and models 
derived from these data would overestimate the productivity effects in typical patients.  There were 
also concerns that different recall periods were used for the HRQoL measure (EQ-5D) and the 
number of days off work.  The EQ-5D recall period was today while productivity information related 
to the previous  6 weeks.  Some individuals who reported full health (EQ-5D=1) also reported having 
a large number of days off work and this may have been a result of the mismatch in recall periods.  
 
The work described in this report was commissioned by the Department of Health to inform its work 
on Value-Based-Pricing (VBP) (Department of Health, 2010), which is due to replace the current 
Pharmaceutical Pricing Regulation Scheme (PPS) in January 2014 for pricing medicines in the UK.  
VBP will include additional payments to interventions that are deemed to provide benefit that is of 
greater social value instead of the current narrow focus on outcomes relevant to the NHS and 
Personal Social Services (PSS).  This requires taking into account wider societal benefits of medicines 
beyond the health of the patient including productivity. 
 
1.1 Objective 
The objective of the analyses was to provide a model to predict productivity losses associated with 
paid work that were representative of all patients that are likely to be seen in the NHS. 
 
2. METHODS 
In order to avoid some of the limitiaions in the existing UK analyses described earlier, an existing 
dataset with both HRQoL and productivity information with similar recall periods was required.  The 
dataset also needed to be representative of typical patients seen by the NHS, and provide both EQ-
5D data and ICD codes.  No datasets were available which satisfied all these criteria.  Two datasets 
which partially satisfied the requirements were identified and data from both datasets were used to 
fill the gaps in the other dataset.  
The first dataset was the Health Outcomes Data Repository (HODaR), the patient dataset used by 
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Rowen et al.(2013).  The second dataset was a general population dataset, Understanding Society 
(US).  HODaR provided HRQoL data (both EQ-5D and SF-36), ICD codes, and information on 
productivity, but had the limitations identified above relating to generalisability and recall periods.  
US contained information on HRQoL based on the SF12 (but not EQ-5D), productivity information 
based on whether or not someone had time off work sick (but not the actual number of days), and 
self-reported health conditions (but not ICD codes).  HODaR was used to develop mapping models to 
predict the SF12 from the EQ-5D, and models to predict the number of days of work.  US was used to 
determine the probability of absence from paid work due to ill health.  The methods section 
describes the data and methods of analysis in more detail. 
2.1 Data 
2.1.1 The Health Outcomes Data Repository 
The Health Outcomes Data Repository (HODaR), is a dataset collated by Cardiff Research Consortium 
(Currie et al.2005).  The data are collected using a prospective survey of recently discharged (within 
previous 6 weeks) inpatients and outpatients at Cardiff and Vale NHS Hospitals Trust, which is a large 
University hospital in South Wales, UK.  The survey is linked to existing routine hospital health data 
to provide a dataset with socio-demographic, HRQoL and ICD classification data.  The survey includes 
all subjects aged 18 years or older and excludes individuals who are known to have died.  The survey 
also excludes people with a primary diagnosis on admission of a psychological illness or learning 
disability.  The sample used in the current analyses is from inpatients and provides 96,282 eligible 
observations across 66,113 individuals discharged from hospital between April 2002 and January 
2009.  A total of 35,126 patients have a primary diagnosis (ICD-10 code) and provide a full set of 
responses for HRQoL, age and gender. 
 
2.1.2 Understanding Society 
Understanding Society (US),  is an annual longitudinal study of 40,000 randomly selected households 
in the UK.  The study was designed to capture social and economic information and attitudes of the 
respondents.  The survey includes HRQoL information (measured using the SF12 instrument) and 
questions relating to employment.  Current health status is self-reported and categorised into 9 
broadly defined condition areas.  The data used in the current analyses were collected during Wave 
1 which covers the years 2009 and 2010 inclusively.  Respondents were excluded if they were proxy 
respondents (n=3,262), aged 66 years or older (n=8,609), or if they had missing SF12 data (n=238).  
This gave a dataset of 26,658 individuals, of which 25% had a self-reported health condition.  The 
five most common conditions were asthma (8.97%), high blood pressure (7.41%), arthritis (6.26%), 
diabetes (2.75%) and clinical depression (2.58%). 
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2.2 Measures 
2.2.1 Demographs 
Information on age and gender was available in both datasets.  Age and gender may be related to 
both health status and productivity. 
2.2.2 Conditions 
The International Classification of Diseases (ICD) is the standard method for classifying diseases and 
other health problems.  The 10th version (ICD-10) (http://www.who.int/classifications/icd/en/) was 
recorded for patients in HODaR.  ICD classifications were recorded in the hospital data as primary 
diagnosis (reason for admission) as well as for secondary diagnosis and these were linked to the 
HODaR survey data.  Consequently, diagnosis was clinically determined in the HODaR data.  In the US 
data, respondents self-reported health conditions from a list limited to 9 very broadly defined 
prevalent conditions. 
 
The HODaR data were sub-grouped according to ICD categories, taking into account the DH 
requirements (i.e. disaggregation for ICD-10 chapters C, E, G, I, J & M where possible), the broad 
programme budget categories (PBC) sub-groups used in recent research on the NICE cost-
effectiveness threshold (Appendix 1 Table A1.1), and the sizes of the resulting sub-groups (sub-group 
size ≥ 100).  The final sub-groups used in the regressions are provided in Appendix 1 Table A1.2. 
 
2.2.3 Health related quality of life 
EQ-5D: The EQ-5D (collected in HODaR) consists of 5 questions describing different dimensions of 
health (Mobility, Self Care, Usual Activities, Pain, Anxiety/depression).  With three possible 
responses to each question this produces a maximum of 243 (5^3) unique health states.  Using 
weights elicited from a sample of the UK general population, the accompanying preference-based 
index (range -0.59 to 1) is anchored at 1 for full health and 0 for death with negative values 
representing health states considered worse than death (Dolan 1997). The EQ-5D is the 
recommended HRQoL measure for health technology assessment (HTA) in England and was the 
required measure for the current project. 
 
SF-36/SF12: The SF-36 was collected in HODaR while the SF12 was collected in US data.  The SF-36 is 
a generic measure of HRQoL with 36 questions.  Responses to these are used to generate two 
summary scores (mental component score (MCS), physical component score (PCS)).  The SF12 is a 
shorter version of the SF-36 consisting of 12 of the 36 questions in the original measure.  There is a 
slight variation in the wording of two of the 12 questions but these are unlikely to elicit different 
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responses.  Both the SF-36 and SF12 can be used to generate the SF-6D, a health state classification 
system with 6 dimensions (Physical, Role, Social, Pain, Mental, Vital).  The dimensions have 4-6 
health states each and have been valued by a representative sample in the UK population using 
standard gamble to generate a preference-based index with values ranging from 0.34 to 1 (Brazier 
2003). 
 
2.2.4 Productivity Loss 
Single item questions were used to record responses related to days off work in both HODaR and US.  
In HODaR, respondents reported the actual number of days off work during the previous six weeks.  
In US, respondents were defined as being off work sick in the previous week if their stated reason for 
being off work was “sick/injured”.  It should be noted that respondents were only able to state one 
reason for being off work in the previous week.  Hence if respondents were sick/injured, but already 
off work due to (say) maternity leave or holiday, then they may not have responded as being off 
work sick.   
 
In addition to productivity information, information on employment status was also required.  In 
HODaR, employment status was reported and this included past employment for those who had 
retired.  As productivity losses from work only relate to those who are employed, using the whole 
sample would likely overestimate the work productivity losses associated with poor health.  To test 
whether this was the case, a smaller sample of individuals who were aged below 66 and were not 
recorded as ‘never worked/unemployed/in full time education’ was used to represent those who 
were likely to be employed at the time they completed the survey.  In US, respondents were defined 
as being in paid work in the previous week if they answered ‘yes’ to either of the following 
questions: ‘did paid work last week’ or ‘no work last week but have paid job’.  
 
2.2.5 Summary overview of datasets 
Patients in the HODaR database are sent a questionnaire within 6 weeks of discharge from hospital.  
While some of the patients who receive the questionnaire will presumably have recovered from the 
acute effects of the health condition for which they were hospitalised, it is reasonable to assume 
that there will be a degree of random variation in recovery time and patients who receive the 
questionnaire relatively soon after discharge will certainly be in the post-hospital recovery stage.  
Suffice to say, as all the respondents have recently been hospitalised, the effects of any relationships 
between EQ-5D scores and time off work identified in these data may not generalise to patients who 
have not been hospitalised recently.  Conversely, respondents in the US database are sampled from 
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the general population which includes respondents with prevalent health conditions who have not 
been hospitalised recently and thus this sample is more representative of the population of interest. 
HRQoL in HODaR is captured using the EQ-5D and the SF-36, whereas HRQoL in US is captured using 
the SF12 questionnaire.  In addition, the differences in the recall period for the EQ-5D (1 day) and 
the time off work sick (6 weeks) in the HODaR questionnaire means that these data are unlikely to 
provide a strong relationship between these variables.  Conversely, the recall periods used in US for 
the SF12 (previous 4 weeks) and time off work sick (previous 1 week) are more likely to show a 
relationship between HRQoL and absence from work due to ill health.  Presence of health conditions 
in HODaR are indicated by clinically noted ICD-10 codes whereas health conditions in US are self-
reported and limited to 9 very broadly defined conditions. 
 
 
3. ANALYSIS 
3.1 Analysis overview 
The relationship between EQ-5D and absence from work due to ill health was explored using the 
following method: 
Step 1: the HODaR and US data were compared using descriptive statistics 
Step 2: a relationship between EQ-5D and SF12 (controlling for age, gender and ICD 
category) was derived from the HODaR data 
Step 3: a relationship between SF12 and absence from work due to ill health (controlling for 
age and gender) was derived from the US data 
Step 4: a relationship to predict the number of days off work, given off work due to ill health, 
(controlling for age, gender and ICD categories) was derived from the HODaR data 
Step 5: the models obtained in Steps 2-4 were used to determine the number of days off 
work due to sickness by EQ-5D and ICD category. 
 
An alternative approach was also used to capture productivity losses, whereby employment was 
used (as opposed to absence from paid employment due to ill health) in Step 3 above. 
3.2 Descriptive statistics 
The HODaR and US descriptive statistics were compared in order to determine how representative 
the HODaR data was.  Comparisons were based on age and HRQoL sub-groups.  The self-reported 
health conditions in the US were “matched” to the ICD codes in HODaR using 9 sub-groups 
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(Appendix 2 Table A2.1) to enable more detailed comparison.  The results of these analysis helped 
inform the subsequent mapping analysis. 
3.3 Exploring the relationship between EQ-5D and SF12 (HODaR data) 
A number of models and regression methods were used to explore possible relationships between 
the two HRQoL instruments including: two-step models combining logistic regressions for the 
extremes, with linear, logit and beta-regression for the other values; and ordered logistic models to 
predict responses for each of the SF12 six health dimensions.  In addition, the effect of using the 
alternative measures available from both the SF12 (SF-6D preference index, MCS-12, PCS-12, 
responses to the six SF12 health dimensions), and the EQ-5D (EQ-5D preference index, responses to 
the EQ-5D health dimensions) were explored.  The results presented here are linear models 
estimated using ordinary least squared (OLS): 
 
Model 1: 
SF-6D =0+*Gender+*Age/10 +i*ICD groupi +… + n*ICD groupn + i*EQ-5D dimension + 
….. + n*EQ-5D dimension +       
Model 2: 
PCS-12 =0+*Gender+*Age/10 +i*ICD groupi +… + n*ICD groupn + i*EQ-5D dimension + 
….. + n*EQ-5D dimension +        
Model 3: 
MCS-12 =0+*Gender+*Age/10 +i*ICD groupi +… + n*ICD groupn + i*EQ-5D dimension 
+ ….. + n*EQ-5D dimension +        
 
For all models, gender (female = 1) and ICD category were modelled as binary data, the EQ-5D health 
dimensions, and age were treated as continuous.  Due to issues with the distribution of the EQ-5D 
preference-based scores, and based on results of exploratory analyses (not shown), the responses to 
the five EQ-5D questions were used as explanatory variables as opposed to the EQ-5D preference 
based index.  There was concern as to how dimension levels would relate to the EQ-5D preference 
scores typically reported in HTA analysis.  223/243 health states have a unique EQ-5D preference-
based score (i.e. the particular EQ-5D score can only be obtained from one specific combination of 
responses to the five questions) while for the remaining 10 EQ-5D preference based scores, each of 
these can be obtained from two different combinations of responses to the five questions.  It is 
therefore possible to use dimensions in the predictions to map to a particular EQ-5D preference 
score.  However, the use of the EQ-5D preference score as an explanatory variable as opposed to the 
EQ-5D dimensions was also explored. 
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3.4 Exploring the relationship between SF12 and absence from work (US data) 
Multivariate logistic regression was performed to model the impact of the variables age, SF measure 
(either SF-6D or PCS_12 and MCS_12) and gender on the probability of being off-work sick.  All of the 
covariates were continuous with the exception of gender.  The possibility of non-linear relationships 
between the continuous variables and the probability of being off-work sick was explored using 
fractional polynomials.  Briefly, each continuous variable was represented by a combination of 
polynomials (either one or two), where the powers for the polynomials are estimated from the data 
and taken from the set {-2, -1, -½, 0, ½, 1, 2, 3}, or the logarithm of the variable is selected.  As there 
were no a priori interactions specified, none were considered. 
 
The results of the fractional polynomial modelling indicated that age and SF-6D could be modelled as 
continuous variables, but the natural logarithm transformation of MCS_12 was required and PCS_12 
should be modelled to the power -2.  These transformations were applied, and the models re-
estimated using logistic regression without centring or scaling any of the covariates (as occurs during 
fractional polynomial logistic regression). 
 
3.5 Number of days off work given the probability of being off work (HODaR) 
The number of days off work in HODaR is recorded as a discrete value (range 1 to 30), with a large 
spike at 30 days.  Count and non-count data models allow these properties to be taken into account 
when modelling the data.  A number of models were tested including Tobit models to take into 
account the bounded nature of the data; two part models to take into account the spike at 30 days; 
and truncated negative binomial models which are count data models and allow the lowest value to 
be a different value from zero.   
 
The spike at 30 days could be generated by a different process to the rest of the days off work, or it 
could represent individuals who are different from the rest of the sample, for example, those who 
are sicker or who are on long-term sickness.  A two-part model was used to model the data to allow 
for this.  The first part used a probit model to predict the probability of having 30 days off work and 
the second part used a truncated negative binomial model for those who have less than 30 days off 
work.  The two parts are combined using an expected value method.  
 
Expected(Days off work) = Probability(30 days off work) + (Predicted days off work < 30)* 
    (1 – Probability(30 days off work)))                                            (4) 
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Previous work indicated that there is over-dispersion in the HODaR days off work data (Rowen et 
al.2013).  As a consequence, a  zero truncated negative binomial model was fit using data from 
employed respondents under the age of 66.  The zero truncated version was used to allow for the 
absence of zeros in the data.  The models were used to predict the number of days off work and the 
final model was selected based on predictive performance across the ICD groups. 
 
3.6 Combining the elements to predict time off work by EQ-5D and ICD 
The elements described above were combined to predict the number of days off work sick as 
follows: 
 
Step 2 (HODaR data) provides the expected SF* (SF-6D, or MCS, PCS) controlled for EQ-5D 
(dimension scores or preference index), age, gender and ICD category 
E(SF*) = f(EQ-5D, age, gender, ICD category) +       
  
Step 3 (US data) provides the probability of being off work sick (OWS) controlled for a SF* (SF-6D, or 
MCS, PCS) score, age and gender 
 P(OWS) = f(SF*, age, gender) +        
 
Step 4 (HODaR data) provides the number of days off work sick (DOWS), given the probability of 
being OWS controlled for age, gender and ICD category  
 E(DOWS | OWS) = f(age, gender, ICD category) +      
 
Combining the above provides the average (mean) number of days off work sick by EQ-5D, age, 
gender and ICD category: 
E(DoWS) = f(age, gender, ICD category)| P(OWS). 
 
As the steps involve probabilities relating to being off work sick, the estimated values cannot equal 
zero days. 
 
3.7 Predicting productivity using employment data (US data) 
In contrast to the previous analyses which measured productivity using the probability of being off 
work sick (US) and the number of days off work sick (HODaR), the analyses below examine 
productivity in terms of whether respondents indicated they did paid employment in the previous 
week in US data. Respondents were defined as being productive in the previous week if they 
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answered ‘yes’ to the following question: ‘Did you do  paid work last week’.  
 
As SF12 may be described using either the SF-6D preference index, or both the mental and physical 
component summary scores (MCS-12 and PCS-12), models were obtained to explore each of these 
relationships.  Two different models were considered; one which included the log of SF-6D, and one 
which included PCS, PCS2, MCS and MCS2. Both models also included gender, age and age2.  Logistic 
regression was used to model the probability of being productive in the last week.  The two models 
were of the form: 
Logit(productivity) =0 +*Age/10 +*(Age/10)
2 +*Gender +*Ln(SF-6D) + (8) 
Logit(productivity) =0 +*Age/10 +*(Age/10)
2 +*Gender +*PCS/10 +*(PCS/10)2 
+*MCS/10 +*(MCS/10)2 +       (9) 
 
 
4. RESULTS 
4.1 Descriptive statistics 
All respondents in HODaR (n=35,126) have at least one condition (Table 1), while just a proportion 
(25%) of respondents in US data (n=25,658) indicate they have a condition (using the self-reported 
responses for the nine named prevalent conditions).  On average, the respondents in HODaR are 
older (mean age 48 vs 40 years), have a lower HRQoL (mean SF-6D 0.689 vs 0.822), with greater 
problems on the SF12 MCS (mean 43.8 vs 53.0) and PCS (mean 47.8 vs 51.2) (Table 1 and Appendix 2 
Figure A2.1). 
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Table 1:  Summary stats for HODaR and US datasets 
 HODaR N=35,126 
(all have at least one condition)  
Understanding Society N=25,658 
(25% have a condition)  
 mean sd mean sd 
Age 47.84 12.81 40.37 12.16 
SF-6D 0.6889 0.1648 0.8223 0.1224 
MCS 43.81 11.61 53.03 7.79 
PCS 47.82 8.64 51.24 8.71 
 N % N % 
SFPhysical     
Not limited 17,314 49.29 23,413 91.25 
Limited a bit 9,907 28.2 1,719 6.70 
Limited a lot 7,905 22.5 526 2.05 
SFRole     
No problems 10,271 29.24 16,848 65.66 
Physical health 7,816 22.25 2,862 11.15 
Emotional problems 2,412 6.87 3,472 13.53 
Physical & emotional problems 14,627 41.64 2,476 9.65 
SFSocial     
Not limited 12,752 36.3 19,795        77.15        
Limited a little 5,841 16.63 2,994        11.67        
Limited some times 8,475 24.13 1,969         7.67        
Limited most times 5,351 15.23 673 2.62        
Limited all the time 2,707 7.71 227 0.88       
SFPain     
No interference 12,047 34.30 17,470        68.09        
A little interference 7,403 21.08 4,670        18.20        
Moderate interference 5,781 16.46 1,622         6.32        
Interferes quite a bit 6,608 18.81 1,260         4.91        
Extreme interference 3,287 9.36 636 2.48       
SFMental     
None of the time 13,267 37.77 13,031        50.79        
A little of the time 10,299 29.32 7,895        30.77        
some of the time 7,046 20.06 3,653 14.24        
Most of the time 3,058 8.71 878 3.42        
All of the time 1,456 4.15 201 0.78       
SFVital     
None of the time 1,341 3.82 2,514         9.80         
A little of the time 8,478 24.14 11,180        43.57        
some of the time 9,760 27.79 8,347        32.53        
Most of the time 7,181 20.44 2,679        10.44        
All of the time 8,366 23.82 938 3.66       
 
When comparing sub-groups of nine broadly defined health conditions in the two datasets, there are 
similar differences in general across the datasets in the characteristics of the sub-groups (Appendix 
2, Table A2.2).  However, there was some similarity when comparing means for the matched groups: 
thyroid, depressive illness, cancer (95% CI overlap for age); depressive illness, cancer (95% CI overlap 
for SF-6D); thyroid, liver, cancer (95% CI overlap for MCS_12); diabetes, thyroid, CHD, cancer (95% CI 
overlap for PCS_12) (see Appendix 2 for more details). 
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Comparing respondents who had time off work due to ill health in the previous week with those who 
did not in US, the mean SF-6D score was lower for those who had been off work than those who had 
not (mean SF-6D=0.62 vs. 0.83) irrespective of whether they indicated that they had a condition or 
not (Table 2).  The percentage of respondents who had been off work was higher in those who 
indicated that they had a condition (192/6684=2.9%) than those who indicated they did not 
(192/18974=1.0%).  Sub-grouping by SF-6D index, the numbers in Figure 1 represent the absolute 
number of respondents who reported they were off work sick.  The percentage of respondents who 
indicated they were off sick increases as their HRQoL decreases, irrespective of whether they 
indicated they had a health condition or not.  Very few respondents who indicate they had good 
HRQoL (SF-6D > 0.8) indicated they were off work sick in the previous week.  When comparing the 
off work sick rates for respondents in the “poor” HRQoL bands (i.e. SF-6D < 0.5), the rate is higher for 
respondents who did not have one of the named conditions.  However, these are very small 
numbers, and presumably, if their HRQoL was this low, it is reasonable to assume that they had a 
condition not identified in the US questionnaire.  This provides an argument that if all conditions are 
not identified by the US questionnaire the full dataset should be used in the regressions, as opposed 
to just the respondents who indicate they had at least one of the named conditions. 
 
Table 2: Comparing US data (respondents with/without a condition) 
  Age  SF-6D  PCS  MCS  
 N mean sd mean sd mean sd mean sd 
US (all)          
Not off sick 25,274 40.31 12.16 0.8253 0.12 53.24 7.49 51.35 8.55 
Off sick 384
 
44.11 12.08 0.6243 0.13 39.18 13.26 43.84 12.08 
US (With condition)         
Not off sick 6,492 45.52 11.98 0.7848 0.13 49.80 9.58 49.80 10.04 
Off sick 192
 
47.64 10.99 0.6029 0.12 36.62 13.73 42.49 15.03 
US (No condition)         
Not off sick 18,782 38.51 11.69 0.8393 0.11 54.43 6.18 51.89 7.90 
Off sick 192
 
40.58 12.11 0.6458 0.14 41.74 12.28 45.20 13.48 
384/26658 = 1.5% who indicate off work sick in previous week; 192/6684 = 2.9% who indicate off work sick in 
previous week; 192/18974 = 1.0% who indicate off work sick in previous week  
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Figure 1:  Off work sick by SF-6D band 
 
 
4.2 Results of regressions to predict the relationship between EQ-5D and SF12 
Using the EQ-5D dimensions as explanatory variables, the results of the SF-6D model show that the 
five EQ-5D dimensions all have the expected signs (as the level of problems increases, HRQoL 
measured using the SF-6D decreases), and are statistically significant (p<0.001) with the largest 
effect observed for the Anxiety/depression dimension (Appendix 3, Table A3.1).  The effects of the 
health conditions (group1 to group56) are in general relatively small compared to the effects of the 
health dimensions and are statistically significant (p<0.05) in less than one third (17/56) of the 
categories.  This is not unexpected as the effects on HRQoL are more appropriately described by the 
responses to the 5 health dimensions as these are more indicative of the SF12 score than the ICD 
group definitions.  The results suggest that as age increases, HRQoL increases (Beta 0.005; p<0.001).  
This is counter-intuitive, as the majority of the literature shows HRQoL decreases by age.  The effect 
is possibly confounded due to the inclusion of the EQ-5D health dimensions as the effects of age will 
likely be captured in these responses. 
 
For the PCS model (Appendix 3, Table A3.1), with the exception of the dimension Anxiety/depression 
the effects for the other four health dimensions are statistically significant (p< 0.001) with Mobility 
and Usual activities having the largest effect.  Conversely, for the MCS model, the effect for the 
dimension Mobility is relatively small compared to the other dimensions, and is not statistically 
18 
 
significant (p=0.075).  Not surprisingly the dimension Anxiety/depression has the largest effect (Beta 
-8.66).  The models for the MCS and PCS scales follow a similar trend to the SF-6D model in terms of 
the relative magnitude of the effects for the health dimensions in comparison to the effects of the 
ICD categories (Groups 1 to 56) and the small number of these that are statistically significant.  
 
All three models predict mean scores for SF-6D, MCS and PCS accurately when sub-grouping by the 
ICD categories (Appendix 3, Table A3.2) although there is reduced variation in the individual level 
predicted scores (data not shown).  There is nothing to choose between the models in terms of 
accuracy in predicting mean scores.  The final model choice (either SF-6D or the MCS_12 and 
PCS_12) will be informed by which of these variables (SF-6D or both MCS_12 and PCS_12) produce 
the most accurate results when used as explanatory variables to predict the probability of being off 
work sick in the US data. 
 
The alternative models (which use the EQ-5D preference-based index as an explanatory variable) 
gave similar results for the ICD groups and age (Appendix 3, Table A3.3).  The EQ-5D preference-
based index has the expected positive effect (SF-6D increases as EQ-5D increases) and is statistically 
significant (p<0.001).  Both models perform well in terms of mean SF-6D scores for categories 
(Appendix 3 Table A3.4) although there is reduced variation in the individual level predicted scores 
when using the EQ-5D preference-based index.  However, when sub-grouping by actual EQ-5D 
preference-based scores (Appendix 3 Table A3.5, Figure 2), and plotting the corresponding observed 
and predicted mean SF-6D preference-based scores, the model using the EQ-5D five health 
dimensions as the explanatory variables outperforms the model using the EQ-5D preference-based 
scores, in the majority of the subgroups. 
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Figure 2: Observed and predicted mean SF-6D scores sub-grouped by EQ-5D scores 
 
 
Graphical comparisons of observed and predicted values against EQ-5D value for each of these 
models are provided in Figure 3.  For each outcome two graphs are displayed; one using the original 
EQ-5D values (of which there are 154 unique values), the other using broad EQ-5D values (calculated 
by rounding the original EQ-5D values to the nearest 0.1, resulting in 17 unique values).  The figures 
indicate that for very low EQ-5D values (less than 0) the model over-predicts values for both SF-6D 
and PCS, but that the predictions for MCS appear reasonable.  However, it should be noted that only 
a small proportion of the dataset has EQ-5D values less than 0 (7%, n = 2,427).  Observed and 
predicted values were also compared for each of the three outcomes (SF-6D, PCS and MCS), for each 
ICD group, and for five sub-groups of EQ-5D values.  These five subgroups were chosen to cover a 
roughly equal number of observations [less than 0.5 (n = 6,246); 0.5 ≤ to < 0.69 (n = 5,991); 0.69 ≤ to 
< 0.79 (n = 6,469); 0.79 <= to < 1 (n = 6,575); = 1 (n = 9,845)]. 
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Figure 3: Observed and predicted values against EQ-5D value 
SF-6D; average observed vs expected by EQ-5D value 
 
 
 
SF-6D; average observed vs expected by broad EQ-5D 
value 
 
PCS; average observed vs expected by   EQ-5D value 
 
 
PCS; average observed vs expected by broad EQ-5D 
value 
 
MCS; average observed vs expected by EQ-5D value 
 
 
MCS; average observed vs expected by broad EQ-5D 
value 
 
 
 
Results showed there was  close agreement between observed and predicted values for each of the 
outcomes across all of the ICD groups and all of the EQ-5D subgroups.  
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4.3 Results of regressions to redict the probability of being off work sick 
Table 3 provides the results for predicting probability of being off work with either SF-6D or MCS and 
PCS as explanatory variables.  Coefficients for the SF12 variables show that the probability of being 
off work sick in the previous week increases with greater SF-6D or PCS_12 values, or lower MCS_12 
values. The estimated effect of age is consistent for all four models, with each increase in age (by a 
year) increasing the log-odds of being off work sick in the previous week by 0.02. The effect for 
gender varies between positive and negative for the different models, but is highly not statistically 
significant for all of the models.  
 
Table 3: Regressions models to predict the probability of being off work sick in the previous week  
 Model 4  Model 5   Model 6  Model 7  
 Coef P>z Coef P>z  Coef P>z Coef P>z 
 N=25533 (full dataset)  N=6619 (respondents with a condition) 
Age 0.02 <0.001 0.02 <0.001  0.02 0.003 0.02 0.007 
Female -0.04 0.683 0.08 0.470  -0.07 0.683 0.07 0.660 
SF-6D -11.32 <0.001 NA NA  -10.15 <0.001 NA NA 
PCS_12 NA NA 8.11 <0.001  NA NA 6.04 <0.001 
MCS_12 NA NA -2.41 <0.001  NA NA -2.16 <0.001 
Constant 3.13 <0.001 -1.89 <0.001  2.58 <0.001 -1.70 <0.001 
          
AUROC 0.8684  0.8684       
Sensitivity 0.52%  3.39%       
Specificity 99.98%  99.91%       
Correctly classified 98.49%  98.46%       
AIC 3110.57  3442.55       
BIC 3143.16  3493.29       
N.B. values for PCS_12 and MCS_12 are both divided by 10. Additionally, the natural logarithm of MCS_12 is 
used, whilst PCS_12 is modelled to the power -2. All four continuous variables were modelled using fractional 
polynomials (up to 2 terms) to explore the possibility of non-linear relationships.  AUROC: Area under the 
receiver operating characteristic curve. AIC: Akaike’s information criteria. BIC: Bayesian information criteria. 
 
 
Using the full dataset, there is a choice between using the model with SF-6D or the model with the 
two summary scores (PCS_12 and MCS_12). Summary measures comparing these two models show 
that there is little to choose between them; both models have area under the receiver operating 
characteristic curve (AUROC) values of 0.864, indicating excellent discrimination. The model with SF-
6D has lower sensitivity (0.52% vs 3.39%), but slightly higher specificity (99.98% vs 99.91%). Overall 
however, the model with SF-6D is to be preferred as it has slightly better performance measures for 
the proportion correctly classified (98.49% vs 98.46%), and lower values for both of the information 
criteria (Akaike’s information criteria (AIC): 3110.57 vs 3442.55, Bayesian information criteria (BIC): 
3143.16 vs 3493.29). 
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The two models were also compared by considering their predictions for different sub-groups, 
defined by their SF-6D value (Appendix 3, Table A3.6).  The model including the explanatory 
variables MCS_12 and PCS_12 gives closer predictions for the ‘medium’ category, but for all the 
other categories the model including the explanatory variables SF-6D provides more accurate 
predictions.  As quality of life decreases, the observed and predicted values show a substantial 
increase in the probability of being OWS in the previous week (Figure 4).  Due to large differences in 
probabilities across the full SF-6D range, Figure 5 shows the results for Groups 5 to 10 on a different 
y-axis. 
 
 
Figure 4: Observed and predicted probabilities of absence from work in previous week by SF-6D  
 
NB: Pred – SF-6D are the predictions from the model which has SF-6D preference-based scores as an 
explanatory variable, Pred – MCS & PCS are the predictions from the model which has the SF12 summary 
scales as explanatory variables. (See Appendix 3, Table A3.6 for SF-6D groupings) 
Figure 5: Observed and predicted probabilities of absence from work (groups 5 to 10 only) 
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NB: Data in Figure 5 are as used in Figure 4, the difference is the y-axis scale 
 
4.4 Results of regressions exploring the number of days off work sick (HODaR) 
Table 4 show the summary statistics of the observed and predicted days-off based on different 
modelling techniques.  The two part model and truncated negative binomial predict the mean well 
but they underestimate the variance around the mean.  When predicted days are grouped by ICD 
code groups, these models perform well (Table A3.7).  However, the two part model missed one 
group (group 30) as those in this group all report less than 30 days off work which means part 1 of 
the model could not be estimated.  The truncated negative binomial model is recommended to 
predict days off (Table A3.8).  The main thing to note about this model is that it does not predict well 
on the lower range with a minimum value of 4.8 days compared to 1 day in the observed data.  This 
is to be expected as the large peak at 30 days is pulling the distribution to the higher values. 
 
Table 4: Comparing observed and predicted days off work  
Variable Mean Std. Dev. Median Minimum Maximum 
Observed 17.6 12.05 20 1 30 
Predicted Tobit 19.2 4.16 19 8.2 29.3 
Predicted two part model 17.0 4.67 16 6.1 29.1 
Predicted  truncated negative binomial 17.1 4.62 16 4.8 31.4 
Predicted negative binomial 8.2 4.05 7 1.0 35.6 
 
4.5 Combining the results 
The number of days of work is estimated as a function of EQ-5D score, age, gender and ICD code.  
Exemplars are provided in Table 5 and an excel spread sheet is available (separate file) which can be 
used to generate the probability of being off work sick, and the average number of days off work 
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sick, given the probability of being off work sick for each age, gender, EQ-5D score and ICD category.   
 
Table 5: Exemplars for number of days of work sick by EQ-5D and ICD category  
ICD group  
(ICD code) 
EQ-5D score Level  
(M,S,U,P,A) 
Age  
(years) 
Gender P(OWS) DOWS|OWS 
Group 51 (A04 ) 1 11111 18 M 0.27% 0.031 
Group 51 (A04) -0.594 33333 18 M 67.74% 7.712 
Group 51 (A04 ) 1 11111 65 M 0.53% 0.089 
Group 51 (A04) -0.594 33333 65 M 80.21% 13.43 
Group 14 (E29) 1 11111 18 M 0.27% 0.026 
Group 14 (E29) -0.594 33333 18 M 67.12% 6.623 
Group 14 (E29) 1 11111 65 M 0.51% 0.075 
Group 14 (E29) -0.594 33333 65 M 79.76% 11.58 
Group 04 (C50) 1 11111 18 F 0.48% 0.090 
Group 04 (C50) -0.594 33333 18 F 78.67% 14.660 
Group 04 (C50) 1 11111 65 F 0.93% 0.254 
Group 04 (C50) -0.594 33333 65 F 87.69% 24.037 
 
 
4.6 Predicting productivity using employment data (US data) 
4.6.1 Descrivitive analysis results 
For this analysis, 61.7% (n = 23,989/38,871) of respondents were classified as being productive in the 
last week.  Responses to the SF12 may be described by either the SF-6D preference-based score 
(observed range: 0.345 to 1) or by both the physical component summary (PCS) score (observed 
range: 11.39 to 66.13) and the mental component summary (MCS) score (observed range: 10.73 to 
68.67).  Summary statistics for these variables are presented in Table 6. 
 
Table 6: Summary statistics for the US data used for the alternative employment analysis 
  
N 
Age SF-6D PCS MCS 
 Mean S.Dev. Mean S.Dev. Mean S.Dev. Mean S.Dev. 
Full dataset 38,871 39.81 13.56 0.7984 0.14 51.30 10.11 50.11 10.15 
Not productive 14,882 39.05 15.66 0.7542 0.16 48.08 12.65 48.01 11.94 
Productive 23,989 40.29 12.04 0.8257 0.12 53.29 7.49 51.42 8.60 
 
Figure 6 shows the distributions of the SF12 variables considered for this analysis.  Figure 6 shows 
the distribution of productivity by age, SF-6D, MCS and PCS (with Wald-based 95% confidence 
intervals).  The figures are on the logit scale, as logistic regression assumes that the association 
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between response and explanatory covariates is a straight-line on this scale.  The figures suggest 
that linear functions are not likely to be good fits.  For SF-6D taking the logarithm looks reasonable, 
for the remaining variables, use of a linear and a squared term appears reasonable.  The graphs 
(with the possible exception of SF-6D) also suggest that separate models may be required for male 
and female genders.  However, for consistency with existing work, gender is included in the models 
as a covariate. 
 
Figure 6: Distribution of SF12 measures 
                    SF-6D                                    PCS                                    MCS 
  
 
 
 
 
Figure 7: Distibution of productivity by age, SF-6D, MCS and PCS    
Productivity in last week by age 
 
Productivity in last week by SF-6D
 
 
Productivity in last week by PCS
 
Productivity in last week by MCS
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4.6.2 Results of regressions estimating employment 
Model coefficients, 95% confidence intervals and p-values are summarised in Table 7.  The summary 
goodness of fit values show that for all of the values considered, the PCS and MCS model shows 
better goodness of fit than the SF-6D model. 
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Table 7:  Model coefficients for the model predicting productivity using employment 
 Model 1 (SF-6D) Model 2 (PCS & MCS) 
 Coef 95% C.I. P>z Coef 95% C.I. P>z 
Age 3.04 (2.93 to 3.14) <0.001 3.00 (2.90 to 3.11) <0.001 
Age
2
 -0.36 (-0.38 to -0.35) <0.001 -0.35 (-0.37 to -0.34) <0.001 
Female -0.48 (-0.53 to -0.44) <0.001 -0.5 (-0.55 to -0.46) <0.001 
Ln(SF-6D) 3.1 (2.98 to 3.22) <0.001 NA NA <0.001 
PCS NA NA NA 1.39 (1.22 to 1.55) <0.001 
PCS
2
 NA NA NA -0.09 (-0.11 to -0.07) <0.001 
MCS2 NA NA NA 1.2 (1.06 to 1.35) <0.001 
MCS
2
 NA NA NA -0.1 (-0.11 to -0.08) <0.001 
Constant -3.59 (-3.79 to -3.40) <0.001 -12.5 (-13.01 to -11.99) <0.001 
       
AUROC  0.7356   0.7513  
Sensitivity  84.70%   86.06%  
Specificity  46.52%   47.92%  
Correctly classified  70.08%   71.45  
AIC  45162.67   44038.39  
BIC  45205.51   44106.93  
Excluding gender       
Age 2.98 (2.88 to 3.08) <0.001 2.95 (2.84 to 3.05) <0.001 
Age
2
 -0.36 (-0.37 to -0.34) <0.001 -0.35 (-0.36 to -0.33) <0.001 
Ln(SF-6D) 3.19 (3.07 to 3.31) <0.001 NA NA NA 
PCS NA NA NA 1.37 (1.20 to 1.53) <0.001 
PCS
2
 NA NA NA -0.09 (-0.11 to -0.07) <0.001 
MCS2 NA NA NA 1.19 (1.04 to 1.33) <0.001 
MCS
2
 NA NA NA -0.09 (-0.11 to -0.07) <0.001 
Constant -4.24 (-4.42 to -4.05) <0.001 -13.2 (-13.70 to -12.70) <0.001 
       
AUROC 0.7255   0.7394   
Sensitivity 85.14%   86.41%   
Specificity 45.62%   46.96%   
Correctly classified 70.01%   71.31%   
AIC 45597.59   44489.63   
BIC 45631.86   44549.61   
N.B. Age, PCS and MCS were all divided by 10 (this was done before squaring PCS and MCS). 
 
Figure 8 shows observed versus expected values for both models.  For consistency all figures use the 
same x-axis (SF-6D).  For each model two graphs are displayed; one using the original SF-6D values 
(of which there are 348 unique values), the other using broad SF-6D values (calculated by rounding 
the original SF-6D values to the nearest 0.02, resulting in 33 unique values).  The Figures show that 
the SF-6D model tends to over-predict productivity at lower health values, whilst the MCS and PCS 
model provides good estimates throughout.  The results from both the goodness of fit measures and 
the graphical comparisons indicate that the MCS and PCS model is to be preferred to the SF-6D 
model.  
 
The analyses looking at the relationship between SF12 and productivity were repeated excluding the 
gender explanatory variable.  Figure 8 show observed versus expected values for both models.  As 
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before, the SF-6D model tends to over-predict productivity at lower health values, whilst the MCS 
and PCS model provides good estimates throughout.  The results from both the goodness of fit 
measures and the graphical comparisons indicate that the MCS and PCS model is to be preferred to 
the SF-6D model.  A comparison of the summary goodness of fit measures presented indicates that 
models which included gender are preferred.  Separate models for males and females may be 
required. 
 
Figure 8: Observed versus expected values for probability of employment by SF-6D 
Model 1 (SF-6D); average observed vs expected by SF-
6D value 
 
 
Model 1 (SF-6D); average observed vs expected by 
broad SF-6D value 
 
Model 2 (PCS-MCS); average observed vs expected by 
SF-6D value 
 
Model 2 (PCS-MCS); average observed vs expected by 
broad SF-6D value 
 
 
4.6.3 Estimating productivity from EQ-5D 
Example productivity estimates were generated for a sample of ICD groups, and a sample of EQ-5D 
states (Table 8, Figure 9).  These examples were generated using both the SF-6D model and the MCS 
and PCS model, for 45-year old females.  The results indicate that there is generally good agreement 
between the method using SF-6D and the method using PCS and MCS, with the exception of EQ-5D 
scores roughly equal to zero.  This may be because both the mapping from EQ-5D to SF-6D and from 
29 
 
SF-6D to productivity were relatively poor for low values of EQ-5D and low values of SF-6D 
respectively.  The results also indicate that there is generally little change in productivity for EQ-5D 
values above about 0.25, with productivity ranging from about 70% to about 85%. 
 
 
Table 8: Estimated productivity in the last week  
(by selected ICD group and EQ-5D preference-based scores) 
 
EQ-5D = -0.255 
(State 2,3,1,3,3) 
EQ-5D = -0.001 
(State 3,3,1,2,1) 
EQ-5D = 0.244 
(State 2,3,1,2,1) 
 SF-6D MCS&PCS SF-6D MCS&PCS SF-6D MCS&PCS 
Group 01 35.36% 32.24% 61.49% 36.70% 70.33% 59.50% 
Group 11 39.66% 36.91% 64.55% 41.40% 72.68% 63.37% 
Group 17 39.75% 39.32% 64.61% 44.85% 72.73% 65.95% 
Group 25 43.26% 39.15% 66.97% 43.81% 74.53% 65.22% 
Group 30 42.77% 40.02% 66.65% 44.82% 74.29% 65.97% 
Group 43 36.09% 29.75% 65.61% 45.21% 73.50% 66.20% 
Group 56 38.93% 31.71% 67.44% 46.71% 74.90% 67.33% 
 
EQ-5D = 0.487 
(State 2,1,3,1,1) 
EQ-5D = 0.746 
(State 2,2,1,1,1) 
EQ-5D = 1 
(State 1,1,1,1,1) 
 SF-6D MCS&PCS SF-6D MCS&PCS SF-6D MCS&PCS 
Group 01 66.36% 59.72% 77.70% 74.27% 82.63% 83.93% 
Group 11 69.04% 63.55% 79.42% 76.71% 83.92% 85.21% 
Group 17 69.10% 66.17% 79.46% 78.29% 83.94% 85.98% 
Group 25 71.16% 65.40% 80.77% 77.85% 84.93% 85.79% 
Group 30 70.88% 66.14% 80.59% 78.30% 84.80% 86.01% 
Group 43 69.98% 66.43% 80.02% 78.44% 84.36% 86.04% 
Group 56 71.57% 67.52% 81.04% 79.12% 85.13% 86.41% 
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Figure 9:  Estimated productivity by selected ICD groups and EQ-5D values 
  
 
 
 
5. DISCUSSION 
The research described above was commissioned to address concerns relating to the 
representativeness of the HODaR respondents compared with the general population, the 
differences in recall periods for the EQ-5D and the periods of absence from work due to illness, and 
the use of the ICD-10 chapter headings.  Results from models that have been developed show that 
they are able to predict productivity losses at the aggregate level.  As decision making is usually 
based on groups of patients, productivity loss estimates from these models may be sufficiently 
accurate.  
 
5.1 Data 
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The approach used in this study involved using two different datasets and it is important to consider 
whether these were suitable for developing the final models.  The comparison of the HODaR and US 
data shows that in general the respondents in the HODaR data are older and have lower HRQoL than 
the general population.  However, comparing matched sub-groups using the self-reported conditions 
in Understanding Society and the corresponding relevant ICD-10 codes in HODaR, the 95% 
confidence intervals of the means overlap for several comparisons and in particular for cancer, 
depressive illness and thyroid.  These results suggest that while the characteristics of the HODaR 
respondents are not directly representative of people in the general population with similar 
conditions, the people are not totally dissimilar and increases confidence in using the HODaR data to 
generalise to patients with some of the health conditions. 
 
The US data exhibit a clear relationship between HRQoL (SF-6D) and reported absence from work 
due to ill health.  The probability of absence from work in these data increases rapidly as quality of 
life decreases.  Very few respondents who indicated they had good HRQoL (SF-6D>0.8) also 
indicated they were off work sick in the previous week.  This is in stark contrast to the results from 
the HODaR data where a substantial proportion of respondents who indicated they were in full 
health (EQ-5D=1) also reported absence from work during the previous 6 weeks due to ill health.  
These results provide support for the critique relating to the difference in recall periods for the 
quality of life instruments and absence of work due to ill health, and provides strong evidence that 
the recall periods used in Understanding Society (SF12: previous 4 weeks; absence from work: 
previous week) are more appropriate than those used in HODaR (EQ-5D: today; absence from work: 
previous 6 weeks).  The use of general population data to represent the probability of absence from 
work due to sickness is also a potential improvement compared to the HODaR data. 
 
In the US data, respondents who reported they did not have one of the named prevalent health 
conditions were also less likely to be off work sick than those who reported they had at least one of 
the conditions (1% vs 3%).  However, when comparing these two sub-groups categorised by SF-6D 
band, the converse is true for respondents with lower levels of quality of life (SF-6D < 0.5) with 
respondents who indicated they did not have a condition being more likely to have been off work 
sick (NB the sample size is relatively small in this comparison).  The latter results may be due to the 
fact that not all health conditions are captured by the named conditions in the US questionnaire.  
However, it also raises concerns relating to the reliability of self-reported conditions compared to 
responses derived from clinically recorded diagnoses, such as in the HODaR data.  Collectively, these 
points indicate that a) it is more appropriate to use the full US dataset when exploring the 
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probability of absence from work, as opposed to using sub-groups of respondents identified by 
positive responses to the health conditions question and b) it is more appropriate to use the HODaR 
data when informing relationships relating to health conditions/ICD-10 codes such as predicting SF-
6D scores controlling for age, gender, EQ-5D responses and ICD category and predicting the number 
of days off work sick, given the probability of absence from work controlling for age, gender and ICD 
category. 
 
Where possible, ICD-10 codes were disaggregated and a total of 57 sub-groups categorised by 3-digit 
ICD-10 codes were used in the current analyses.  Subject to the number of respondents in the 
HODaR data, the selections for the final sub-groups were informed by the preferred categories 
provided by the DH, and the programme budget categories (PBC) used in a related piece of research.  
Despite the relatively large sample from HODaR (n=35,126), it was not possible to cover every 
possible health condition defined in the ICD-10 dictionary, but it should be possible to identify 
“similar” conditions for those ICD-10 codes which are not explicitly mentioned. 
 
5.2 Existing data 
There is little existing literature looking at the relationship between EQ-5D and productivity.  Lamers 
et al.considered days absent from work in the last 6-weeks and EQ-5D scores (Lamers 2005) 
However, they looked at average EQ-5D score by productivity, as opposed to average productivity by 
EQ-5D score, hence the results cannot be directly compared with those reported from US.  However, 
the authors found that lower rates of productivity had lower average EQ-5D scores, consistent with 
the association observed for this work. 
 
Krol looked at estimating productivity by EQ-5D health state where health state was defined using 
the possible responses to the five EQ-5D health dimensions.(Krol 2012)  Productivity was assessed 
via an online questionnaire, where a sample of the Dutch general population (n = 1,100) were asked, 
hypothetically, what proportion of people would be absent from work for given EQ-5D health states. 
Results were presented for 40-year old males, and use the Dutch national tariff for EQ-5D (as 
opposed to the United Kingdom tariff used for this work).  Selected comparisons between the results 
found by Krol and those found in this study (Appendix 3, Table A3.9).  They show close agreement 
for the EQ-5D states “1,1,1,1,1” and “2,2,1,1,1”, but large disagreement for the remaining states, 
with the estimates produced for this work much greater than the estimates produced by Krol.  It 
should be noted that the estimates produced by Krol are based on hypothetical productivity levels, 
as opposed to observed levels of productivity. 
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5.3 Limitations 
There are limitations with the research presented here.  Firstly, it is never ideal to use a “double 
mapping” approach.  However, the comparisons of the observed and predicted values illustrate that 
the individual models perform extremely well on the aggregate level for all the sub-groups tested.  
While the end product (the number of days off work for each age, gender, ICD group and EQ-5D 
score) appear reasonable, it is not currently possible to validate these predictions in external data as 
such data do not exist.  A second related limitation is that the predictions are currently limited to 
point estimates.  It would be more appropriate to characterise the uncertainty around these 
estimates but this was not possible due to the time constraints of the current project.   
 
Thirdly, although the US data are used to determine the probability of absence from work due to ill 
health, the current analyses retain the HODaR data for estimating the number of days off work.  It is 
possible that the total number of days of work due to ill health is over-estimated by using the data 
from people who have been recently discharged from hospital.  However, as mentioned previously, 
a proportion of the HODaR patients will have recovered from the effects of the condition or event 
they were hospitalised for, and given that the probability of being off work is derived from the 
general population, it is not believed that the over-estimation would be substantial.   
 
Finally, although the data were sub-grouped by ICD-10 categories, it was not possible to identify 
either severity or duration of the particular conditions.  However, as the EQ-5D health dimensions 
are used as explanatory variables, the additional knowledge of disease duration and or disease 
severity could possibly confound these effects.  Further work is undeway to collect more robust data 
that can be used to address the limitations addressed here.  In addtion, external validation of the 
models presented here needs to be undertaken once suitable data are available. 
 
5.4 Summary 
The analysis reported here allows productivity losses associated with HRQoL based on EQ-5D and 
ICD codes to be predicted for inclusion in health technology assessment.  It addressed some of the 
limitations of existing work using two datasets. The results show that models can predict 
productivity accurately at the aggregate level.  Further work is recommended to valdate these 
models as well as primary data collection of productivity and HRQoL to avoid the ‘double-mapping’ 
approach used here. 
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APPENDIX 1:  International Classification of Diseases 
Table A1.1: PBC groups (Source: CHE Research Paper 81) 
PBC  Definition ICD10 categories         
01 Infectious Diseases B20-B24 A30-A49 A20-A28 A90-A99 A75-A79 A65-A69 
  B00-B09 B35-B49 B50-B64 B25-B34 B65-B83 B85-B89 
  A80-A89 B98-B99 R50-R69 R70-R99 Z20-Z29 Z80-Z99 
02 Cancer & Tumours C50-C58 C15-C26 C60-C63 C64-C68 C30-C39 C81-C96 
  C43-C44 C45-C49 C76-C80 C69-C72 C00-C14 C73-C75 
  J95-J99 C40-C41 C97- D00-D09 D10-D36 D37-D48 
  N30-N39 Z00-Z13 Z40-Z54 Z80-Z99   
03 Disorders of Blood  D60-D64 D50-D53 D70-D77 D80-D89 D55-D59 D65-D69 
  Q80-Q89 R70-R99     
04 Endocrine, Nutritional & 
Metabolic Issues 
E10-E14 E79-E90 E00-E07 E24-E27 E28-E30 E31-E35 
 E70-E72 E15-E16 E20-E21  E22-E23 E65-E68 E73-E74 
  E76-E78 E75 E50-E64 E40-E46 R50-R69 R70-R99 
05 Mental Health Disorders F10-F19 F30-F39 F40-F48 F50-F59 F00-F09 F20-F29 
  G30-G32 F60-F69 F90-F98 F99 Z55-Z65  
06 Problems of Learning 
Disability 
F80-F89 F70-F79 Q90-Q99 F90-F98 Z80-Z99  
07 DNeurological G40-G47 G20-G26 G30-G32 G90-G99 G50-G59 G35-G37 
  G60-G64 G80-G83 G00-G09 G10-G13 G70-G73 A80-A89 
  H90-H95 Q00-Q07 B00-B09 N30-N39 A30-A49 B25-B34 
  B65-B83 A15-A19 B50-B64 R00-R09 R20-R23 R25-R29 
  R30-R39 R40-R46 R47-R49 R50-R69 R70-R99 Z80-Z99 
08 Problems of Vision H49-H52 H40-H42 H25-H28 H00-H06 H30-H36 H15-H19 
  H55-H59 H10-H13 H20-H22 H43-H45 H46-H48 H53-H54 
  A70-A74 B25-B34 B50-B64 B65-B83 Q10-Q18 Z40-Z54 
  Z80-Z99      
09 Problems of Hearing H90-H95 H65-H75 H80-H83 H60-H62 Q10-Q18  
10 Problems of Circulation I20-I25 I60-I69 Q20-Q28 I30-I52 I80-I89 I70-I79 
  I10-I15 I26-I28 I95-I99 I00-I02 I05-I09 B50-B64 
  R00-R09 R50-R69 Z40-Z54 Z80-Z99   
11 Problems of Respiratory 
System 
J40-J47 J00-J06 J09-J18 J60-J70 J30-J39 J20-J22 
 J80-J84 J90-J94 J95-J99 A30-A49 J85-J86 B35-B49 
 A15-A19 A70-A74 B25-B34 R00-R09 R70-R99 Z00-Z13 
  Z40-Z54 Z80-Z99 Q30-Q34    
12 Dental Problems K00-K14      
13 Problems of the Gastro 
Intestinal System 
A00-A09 K20-K31 K35-K38 K55-K63 K70-K77 K80-K87 
 K50-K52 K65-K67 K90-K93 Q35-Q45 B65-B83 I80-I89 
  B15-B19 K00-K14 A20-A28 A65-A69 A90-A99 B35-B49 
  R10-R19 R70-R99 Z80-Z99    
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PBC  Definition ICD10 categories         
14 Problems of the Skin L80-L99 L60-L75 L20-L30 L00-L08 L40-L45 L10-L14 
  L50-L54 L55-L59 N30-N39 B00-B09 B35-B49 B85-B89 
  A20-A28 A30-A49 A65-A69 Q80-Q89 Z40-Z54 Z80-Z99 
  R20-R23 R70-R99 T20-T32    
15 Problems of the 
Musculoskeletal System 
M15-M19 M05-M14 M45-M49 M80-M90 M70-M79 M20-M25 
 M30-M36 M40-M43 M50-M54 M91-M94 M60-M63 M65-M68 
  M95-M99 M00-M03 A15-A19 Q65-Q79 Q10-Q18  
  Q80-Q89 Z40-Z54     
16 Problems due to Trauma 
and Injuries 
S00-S99 T00-T79 Z57-Z59    
17 Problems of the Genito-
urinary System 
N30-N39 A50-A64 N25-N29 I10-I15 N00-N08 N20-N23 
 N10-N16 N17-N19 B25-B34 Q60-Q64 B65-B83 Q50-Q56 
  R30-R39 R70-R99 Z40-Z54 Z80-Z99   
18, 19 Maternity and 
Reproductive Health & 
Conditions of Neonates 
O30-O48 O60-O75 P05-P08 O20-O29 O80-O84 P20-P29 
 O85-O92 O95-O99 P10-P15 P50-P61 P90-P96 P00-P04 
 P35-P39 P70-P74 N30-N39 P75-P78 P80-P83 O10-O16 
  A30-A49 O00-O08 A30-A49 R70-R99 Z30-Z39 Z80-Z99 
20 Adverse Effects and 
Poisoning 
O85-O92 O95-O99 K90-K93 O20-O29 O60-O75 L55-L59 
  L60-L75 Q80-Q89 R70-R99 T36-T50 T51-T65 T66-T78 
  T80-T88 Z80-Z99 O00-O08 N30-N39   
21 Health Individuals E65-E68 E76-E78 Z00-Z13 Z20-Z29 Z40-Z54 Z55-Z65 
22 Social Care Needs Z74-Z75      
23 Other areas of 
Spend/Conditions 
Q92-Q99 R53-R98 Z09-Z91       
Source: K Claxton, S Martin, M Soares, N Rice, E Spackman, S Hinde, N Devlin, P C Smith,  M Sculpher. Methods 
for the Estimation of the NICE Cost Effectiveness Threshold. CHE Research Paper 81. 
37 
 
Table A1.2: ICD-10 codes as used in the ICD groups in the current project 
ICD 
 Group Definition of health condition and corresponding ICD-10 codes 
1 Malignant neoplasms of digestive organs 
 C15 C16 C17 C18 C19 C20 C21 C22 C24 C25 C26    
2 Malignant neoplasms of respiratory and intrathoracic organs 
 C30 C31 C32 C34 C37 C38         
3 Melanoma and other malignant neoplasms of skin, mesothelial and soft tissue 
 C43 C44 C45 C48 C49          
4 Malignant neoplasm of breast 
 C50              
5 Malignant neoplasms of female genital organs 
 C51 C52 C53 C54 C55 C56 C57        
6 Malignant neoplasms of male genital organs 
 C60 C61 C62 C63           
7 Malignant neoplasms of urinary tract 
 C64 C67             
8 Malignant neoplasms, stated or presumed to be primary, of lymphoid, haematopoietic and related 
tissue  C81 C82 C83 C84 C85 C88 C90 C91 C92 C96     
9 In situ neoplasms 
 D00 D01 D02 D03 D04 D05 D06 D07 D09     
10 Benign neoplasms 
 D10 D11 D12 D13 D14 D15 D16 D17 D18 D19 D21 D22 D23 D24 
 D25 D26 D27 D28 D29 D30 D31 D32 D33 D34 D35 D36  
11 Neoplasms of uncertain or unknown behaviour 
 D37 D38 D39 D40 D41 D42 D43 D44 D45 D46 D47 D48  
12 Diseases of the blood and blood-forming organs and certain disorders involving the immune 
mechanism  D50 D51 D52 D53 D57 D58 D59 D61 D64 D66 D67 D68 D69 D70 
 D72 D73 D75 D80 D83 D84 D86 D89 Q89     
13 Diabetes mellitus 
 E10 E11 E14            
14 Other disorders of glucose regulation, pancreatic internal secretion, of endocrine glands  
 E16 E20 E21 E22 E23 E24 E26 E27 E28 E29 E31 E32 E34  
15 Endocrine, Nutritional & Metabolic Issues 
 E46 E53 E61 E71 E72 E75 E80 E83 E84 E85 E86 E87 E88 E89 
16 Disorders of thyroid gland 
 E03 E04 E05 E06 E07          
17 Mental Health Disorders 
  F06 F07 F10 F11 F13 F15 F30 F41 F43 F45 F50 F51 F52 F62 
  F64 F80 R63 R74 R79 Z72         
18 Demyelinating diseases of the central nervous system 
  G35 G37            
19 Episodic and paroxysmal disorders 
 G40 G41 G43 G44 G45 G47        
20 Nerve, nerve root and plexus disorders 
 G50 G51 G52 G54 G56 G57 G58       
21 Other disorders of the nervous system 
  G60 G61 G62 G70 G71 G72 G80 G81 G82 G83 G90 G91 G93 G95 
  G96 G97 G98           
22 Infectious Disease not covered elsewhere 
 B58 H00 H01 H02 H04 H05 H10 H11 H16 H17 H18 H20 H21 H27 
 Q10 Z46             
23 Disorders of lens 
 H25 H26            
24 Disorders of choroid and retina 
 H30 H33 H34 H35          
25 Diseases of the eye and adnexa 
 H40 H43 H44 H46 H47 H49 H50 H51 H52 H53 H54 H57 H59 
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ICD 
 Group Definition of health condition and corresponding ICD-10 codes 
26  Diseases of the ear and mastoid process 
  H60 H61 H65 H66 H69 H70 H71 H72 H73 H74 H80 H81 H83 H90 
27 Ischemic Heart Diseases 
  I20 I21 I22 I23 I25 I26         
28  Hypertensive disease and cerebrovascular diseases 
  I10 I11 I12 I60 I61 I62 I63 I64 I65 I66 I67    
29 Diseases of arteries, veins and lymphatic vessels and nodes 
 I70 I71 I72 I73 I74 I77 I78 I80 I82 I83 I84 I85 I86 I87 
30 Acute upper respiratory infections 
 J00 J01 J02 J03 J04 J05 J06        
31 Influenza and pneumonia 
 J10 J11 J12 J13 J14 J15 J18        
32 Other acute lower respiratory infections 
 J20 J21 J22            
33 Other diseases of upper respiratory tract 
 J30 J31 J32 J33 J34 J35 J36 J37 J38 J39     
34 Chronic lower respiratory diseases 
 J40 J42 J43 J44 J45 J47         
35 Problems of Respiratory System not covered elsewhere 
 J64 J67 J69 J81 J82 J84 J85 J86 J90 J92 J93 J94 J95 J96 
36 Arthropathies and arthrosis 
 M00 M05 M06 M08 M10 M11 M12 M13 M15 M16 M17 M18 M19 M20 
 M21 M22 M23 M24 M25 M30 M31 M32 M33 M34 M35    
37 Dorsopathies 
 M40 M41 M42 M43 M45 M46 M47 M48 M50 M51 M53 M54   
38 Disorders of muscles, synovium and tendon and other soft tissues 
 M60 M62 M65 M67 M70 M71 M72 M75 M76 M77 M79    
39 Disorders of bone density & structure, osteopathies and chondropathies 
 M80 M81 M84 M86 M87 M89 M92 M93 M94      
40 Diseases of the genitourinary system (1) 
 N02 N04 N05 N06 N10 N12 N13 N17 N18 N19 N20 N21 N23 N25 
 N28 N30 N31 N32 N35 N36 N39        
41 Diseases of male genital organs 
 N40 N41 N43 N44 N45 N47 N48 N49 N50     
42 Diseases of the genitourinary system (2) 
 N46 N61 N62 N64 N70 N71 N72 N73 N75 N76 N80 N81 N82 N83 
 N84 N85 N86 N87 N88 N89 N90 N91 N92 N93 N95 N97 N98 N99 
43 Infectious Diseases (1) 
 A40 A41 A48 A49 B20 B23 B24 B27 B34 B51 B59 B60 B99 R50 
 Z22 Z83             
44 Cancer & Tumours not identified in other groups 
 C00 C01 C02 C03 C04 C06 C07 C09 C11 C41 C69 C70 C71 C72 
 C73 C75 C76 C77 C78 C79 C80 N60 N63 Z08 Z51 Z80 Z85  
45 Cancer & Tumours not identified in other groups (2) 
 Q99 R53 R54 R59 R60 R82 R89 Z09 Z48 Z52 Z53 Z54 Z76 Z91 
46 DNeurological   
 A39 A86 A87 B01 B02 B50 G00 G03 G06 G08 G10 G11 G12 G20 
 G21 G23 G24 G25 G31 N94 Q04 Q05 Q06 Q07 R07 R20 R25 R26 
 R27 R29 R30 R40 R41 R42 R45 R47 R49 R51 R52 R55 R56 R61 
 R90 R93 R94            
47 Problems of the Gastro Intestinal System  
 K91 L56 O08 O86 O90 R78 T36 T38 T39 T40 T41 T42 T43 T44 
 T45 T46 T48 T49 T50 T51 T52 T54 T56 T62 T63 T65 T78 T81 
 T82 T83 T84 T85 T86 T87 T88 T91 Z88      
48 Problems of Circulation not covered elsewhere 
 I05 I06 I07 I08 I27 I28 I30 I31 I33 I34 I35 I38 I42 I44 
 I45 I46 I47 I48 I49 I50 I51 Q21 Q23 Q24 Q25 Q27 Q28 R00 
 R01 R02 R03 Z45 Z50          
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ICD 
 Group 
Definition of health condition and corresponding ICD-10 codes 
49 Problems of Respiratory System not covered elsewhere 
 A15 A31 B25 B44 Q33 R04 R05 R06 R09 R91 Z03 Z43 Z87 Z93 
50 Diseases of oral cavity, salivary glands and jaws 
 K00 K01 K02 K04 K05 K06 K07 K08 K09 K10     
51 Problem Gastro intestinal system including gallbladder, pancreas, peritoneum, liver, digestive system 
 A04 A06 A07 A08 A09 B15 B16 B18 B19 B37 B67 K11 K12 K13 
 K14 K20 K21 K22 K25 K26 K27 K29 K30 K31 K35 K37 K38 K40 
 K41 K42 K43 K44 K45 K46 K50 K51 K52 K55 K56 K57 K58 K59 
 K60 K61 K62 K63 K65 K66 K70 K71 K72 K73 K74 K75 K76 K80 
 K81 K82 K83 K85 K86 K90 K92 Q38 Q39 Q43 R10 R11 R12 R13 
 R14 R15 R17 R18 R19 Z98         
52 Problems of the Skin 
 A46 B00 B07 B08 B35 B36 L02 L03 L04 L05 L08 L10 L12 L20 
 L23 L27 L28 L29 L30 L40 L42 L43 L50 L51 L52 L53 L57 L60 
 L66 L68 L70 L71 L72 L73 L74 L81 L82 L84 L85 L88 L89 L90 
 L91 L92 L94 L95 L97 L98 Q82 Q83 Q84 Q85 R21 R22 R23 R92 
 Z41 Z42             
53 Problems due to Trauma and Injuries 
 S00 S01 S02 S03 S05 S06 S09 S10 S11 S12 S13 S14 S19 S20 
 S21 S22 S23 S26 S27 S29 S30 S31 S32 S33 S35 S36 S37 S39 
 S41 S42 S43 S46 S49 S50 S51 S52 S53 S56 S60 S61 S62 S63 
 S64 S66 S68 S69 S70 S71 S72 S73 S76 S80 S81 S82 S83 S86 
 S89 S90 S91 S92 S93 S96 S99 T02 T08 T13 T14 T15 T16 T17 
 T18 T19 T21 T70 T79          
54 Problems of the Genito-urinary System 
 A52 A56 A60 A63 B26 Q52 Q53 Q54 Q55 Q61 Q64 R31 R32 R33 
 R35 R36 R39 R80 R86 R87 Z94 Z96       
55 Problems of Respiratory System not covered elsewhere 
 A18 M95 M96 Q18 Q66 Q76 Q78 Q79 Z44 Z47     
56 Maternity and Reproductive Health & Conditions of Neonates 
 O00 O01 O02 O03 O04 O06 O10 O12 O13 O14 O15 O16 O20 O21 
 O23 O26 O30 O32 O33 O34 O35 O36 O40 O41 O42 O43 O44 O45 
 O46 O47 O48 O60 O61 O62 O63 O64 O66 O68 O69 O70 O72 O75 
 O80 O82 O98 O99 Z30 Z31 Z34 Z35 Z36 Z37 Z38 Z39 Z92  
 Healthy 
 E78 Z00 Z01 Z04 Z12 Z13 Z26 Z29 Z40 Z63 Z71 Z75   
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APPENDIX 2: COMPARING HODAR AND US DATA 
 
Table A2.1: Groups used when matching the ICD in HODaR to the conditions in Understanding Society 
 HODaR Understanding Society 
Group N ICD codes  N Self-reported “Current” condition 
1 468 J20-J22 Other acute lower 
respiratory infections 
2371 Asthma,  
emphysema,  
bronchitis   J40-J47 Chronic lower respiratory 
diseases 
 
2 4457 M05-M95 Diseases of the 
musculoskeletal system and 
connective tissue 
1,613 Arthritis 
3 3331 I10-I15 Hypertensive diseases 181 Congestive heart failure,  
CHD, angina, heart attack or MI,  
stroke,  
HBP 
  I20-I25 Ischaemic heart diseases  
  I26-I28 Pulmonary heart disease and 
diseases of pulmonary 
circulation 
 
  I30-I50 Other forms of heart disease  
  I60-I69 Cerebrovascular diseases   
4 106 E00-E07 Disorders of thyroid gland 570 Hyperthyroid 
Hypothyroid 
5 97 K70-K77 Diseases of liver 127 Any Liver Condition 
6 3422 C00-D48 Neoplasms 110 Cancer/malignancy 
7 148 E10-E14 Diabetes mellitus 714 Diabetes 
8 271 G40-G47 Episodic and paroxysmal 
disorders 
116 Epilepsy 
9 74 F00-F99 Mental and behavioural 
disorders 
658 Clinical depression 
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Figure A2.1: Comparing the data in HODaR and Understanding Society 
HODaR (full dataset) Understanding Society (full dataset) 
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Comparing the matched sub-groups (n=9), the summary statistics in Table A2.2 show, on average the groups in 
HODaR are:  
 older (except DM)  
 have lower HRQoL scores (except MCS for clinical depression)  
 greater proportions report problems on all health dimensions (data not shown) 
 
Table A2.2:  Summary stats from HODaR & US for 9 Broad conditions groups 
  HODaR US HODaR US HODaR US 
  mean sd mean sd mean sd mean sd mean sd mean sd 
 Respiratory Arthritis CHD 
N 468  2371  4457  1613  3331  181  
Age 49.60 12.75 39.84 12.5 59.65 11.37 51.25 9.31 55.66 8.14 53.32 9.96 
SF-6D 0.642 0.16 0.792 0.13 0.6205 0.16 0.7471 0.14 0.655 0.15 0.750 0.14 
MCS 45.67 9.38 50.03 9.65 47.65 8.88 50.67 10.4 47.56 8.46 50.93 9.49 
PCS 38.97 11.97 50.54 9.34 37.44 11.62 44.58 11.9 40.30 11.19 42.2 11.8 
 Diabetes Epilepsy Depress 
N 148  714  271  116  74  658  
Age 44.33 13.49 49.63 9.94 45.19 13.23 39.91 11.84 45.04 11.64 42.36 11.04 
SF-6D 0.6802 0.15 0.7818 0.14 0.6613 0.16 0.7872 0.13 0.619 0.13 0.6519 0.12 
MCS 45.62 9.14 50.89 9.78 45.72 8.84 49.68 9.50 42.07 9.01 37.07 12.35 
PCS 44.37 11.57 46.77 10.05 42.81 11.90 50.2 8.92 43.62 11.12 50.03 11.17 
 Thyroid Liver Cancer 
N 106  570  97  127  3422  110  
Age 46.41 11.21 47.4 10.33 49.96 9.10 45.72 11.12 50.66 11.46 48.61 10.59 
SF-6D 0.7226 0.14 0.7778 0.13 0.6119 0.16 0.7383 0.14 0.7073 0.16 0.7202 0.16 
MCS 48.09 8.48 49.36 9.32 44.27 11.27 46.48 11.08 48.55 7.88 48.75 10.53 
PCS 47.03 9.40 49.67 9.71 38.52 11.46 45.93 10.95 45.13 11.19 42.19 12.77 
 
 
 
While the results reported in the main report show differences in the characteristics of the sub-groups, the 
95% confidence intervals of the mean overlap for some matched groups for age (thyroid, depressive illness, 
cancer, Figure A2.1), SF-6D (depressive illness, cancer, Figure A2.2), MCS_12 (thyroid, liver, cancer, Figure 
A2.3) and PCS_12 (diabetes, thyroid, CHD, cancer, Figure A2.4). 
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Figure A2.1: Comparing mean age for matched sub-groups in HODaR and Undestanding Society 
 
 
Figure A2.2: Comparing mean SF-6D for matched sub-groups in HODaR and Undestanding Society 
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Figure A2.3: Comparing mean MCS_12 for matched sub-groups in HODaR and Undestanding Society 
 
 
 
Figure A2.4: Comparing mean PCS_12 for matched sub-groups in HODaR and Undestanding Society 
 
 
 
 
 
 
45 
 
APPENDIX 3: Additional tables and figures 
Table A3.1:  Regression models to predict SF-6D, MCS, or PCS scores (using EQ-5D health dimensions) 
  SF-6D Robust   PCS_12 Robust    MCS_12 Robust   
 Coef. Std. Err. P>t Coef. Std. Err. P>t Coef. Std. Err. P>t 
Age/10 0.0053 0.0005 <0.001 -0.3081 0.0285 <0.001 0.7701 0.0282 <0.001 
Sex -0.0154 0.0011 <0.001 -0.6485 0.0736 <0.001 -0.2462 0.0712 0.001 
Mobility -0.0462 0.0016 <0.001 -5.9385 0.1154 <0.001 0.1827 0.1026 0.075 
Self_Care -0.0285 0.0014 <0.001 -4.0015 0.1286 <0.001 -1.3176 0.1192 <0.001 
Usual_Act -0.0735 0.0012 <0.001 -6.3047 0.0893 <0.001 -1.3089 0.0848 <0.001 
Pain -0.0542 0.0011 <0.001 -4.4361 0.0754 <0.001 -1.0195 0.0733 <0.001 
Anxiety -0.0906 0.0009 <0.001 0.0900 0.0683 0.188 -8.6647 0.0711 <0.001 
group01 -0.0328 0.0107 0.002 -3.2109 0.7726 <0.001 -1.1575 0.6675 0.083 
group02 -0.0373 0.0122 0.002 -3.7750 0.8929 <0.001 -2.0939 0.8400 0.013 
group03 0.0341 0.0095 <0.001 1.0431 0.5328 0.050 0.6035 0.5214 0.247 
group04 -0.0252 0.0099 0.011 -0.8522 0.5896 0.148 -1.2922 0.5788 0.026 
group05 -0.0308 0.0115 0.008 -3.2474 0.7193 <0.001 -0.8251 0.7076 0.244 
group06 -0.0214 0.0126 0.091 -0.9201 0.7351 0.211 -0.1408 0.7039 0.842 
group07 -0.0224 0.0128 0.081 -1.4133 0.7722 0.067 -1.3099 0.7106 0.065 
group08 -0.0090 0.0099 0.363 -2.5096 0.6203 <0.001 -0.6381 0.6110 0.296 
group09 0.0085 0.0111 0.443 0.1511 0.6504 0.816 -0.1330 0.6059 0.826 
group10 0.0182 0.0089 0.042 0.6678 0.4990 0.181 0.0468 0.4915 0.924 
group11 -0.0090 0.0124 0.468 -1.3983 0.7013 0.046 -0.3593 0.7113 0.613 
group12 0.0124 0.0096 0.194 -0.5465 0.5601 0.329 0.4641 0.5430 0.393 
group13 -0.0004 0.0111 0.970 -0.5811 0.7360 0.430 -1.3031 0.7079 0.066 
group14 0.0152 0.0099 0.125 0.1428 0.5644 0.800 0.0104 0.5643 0.985 
group15 0.0162 0.0116 0.165 -1.3575 0.7184 0.059 1.1601 0.6741 0.085 
group16 0.0027 0.0125 0.826 -0.2922 0.7058 0.679 -0.9385 0.7573 0.215 
group17 -0.0085 0.0118 0.472 0.2512 0.7501 0.738 -0.9959 0.7087 0.160 
group18 0.0090 0.0105 0.389 -2.5299 0.7898 0.001 1.7135 0.6737 0.011 
group19 0.0086 0.0102 0.396 -0.0295 0.6023 0.961 -0.3246 0.6242 0.603 
group20 0.0225 0.0098 0.022 0.5933 0.5617 0.291 0.7043 0.5527 0.203 
group21 0.0069 0.0105 0.507 -0.7326 0.6747 0.278 1.2727 0.6469 0.049 
group22 0.0229 0.0110 0.037 0.7712 0.6556 0.239 -0.2229 0.6149 0.717 
group23 0.0298 0.0099 0.003 0.7590 0.5559 0.172 0.0382 0.5572 0.945 
group24 0.0024 0.0105 0.818 0.7741 0.6056 0.201 -1.0544 0.6183 0.088 
group25 0.0112 0.0107 0.294 -0.4088 0.6190 0.509 -0.1758 0.6222 0.777 
group26 0.0282 0.0108 0.009 0.9383 0.5956 0.115 0.3034 0.5898 0.607 
group27 -0.0097 0.0087 0.264 -1.6308 0.4923 0.001 -0.1244 0.4863 0.798 
group28 -0.0128 0.0100 0.201 -1.6836 0.6064 0.005 -1.0826 0.5903 0.067 
group29 0.0243 0.0090 0.007 0.9893 0.5077 0.051 -0.1095 0.5034 0.828 
group30 0.0085 0.0133 0.524 0.0195 0.6552 0.976 -0.1662 0.6936 0.811 
group31 -0.0071 0.0111 0.522 -1.8423 0.6451 0.004 -0.8846 0.6537 0.176 
group32 0.0085 0.0120 0.480 0.1504 0.7684 0.845 -0.0729 0.7053 0.918 
group33 0.0315 0.0095 0.001 0.9167 0.5214 0.079 -0.0605 0.5251 0.908 
group34 0.0073 0.0099 0.461 -1.9856 0.5917 0.001 -0.7706 0.5999 0.199 
group35 -0.0020 0.0113 0.858 -2.4050 0.7312 0.001 0.2380 0.6884 0.730 
group36 0.0139 0.0087 0.111 0.2564 0.4964 0.605 1.4096 0.4888 0.004 
group37 -0.0043 0.0088 0.620 -1.4465 0.5051 0.004 1.2143 0.4982 0.015 
group38 0.0150 0.0092 0.103 0.4508 0.5198 0.386 0.7464 0.5143 0.147 
group39 0.0123 0.0112 0.271 -0.2609 0.7318 0.721 0.4512 0.7158 0.528 
group40 0.0115 0.0092 0.214 0.0891 0.5212 0.864 -0.1228 0.5195 0.813 
group41 0.0293 0.0109 0.007 0.5803 0.6141 0.345 0.7713 0.5856 0.188 
group42 0.0130 0.0088 0.138 0.5559 0.4906 0.257 -0.1577 0.4889 0.747 
group43 -0.0003 0.0122 0.982 0.4926 0.6971 0.480 -1.3068 0.6844 0.056 
group44 0.0081 0.0094 0.390 -0.6871 0.5577 0.218 -0.1641 0.5328 0.758 
group45 0.0155 0.0097 0.109 0.2369 0.5582 0.671 -0.0051 0.5526 0.993 
group46 0.0070 0.0088 0.426 -0.3506 0.4967 0.480 -0.4128 0.4905 0.400 
group47 -0.0088 0.0090 0.330 -0.0635 0.5240 0.904 -1.5944 0.5328 0.003 
group48 0.0093 0.0089 0.299 -1.0365 0.5142 0.044 0.6955 0.5018 0.166 
group49 0.0125 0.0095 0.187 -0.8383 0.5540 0.130 0.1109 0.5372 0.836 
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  SF-6D Robust   PCS_12 Robust    MCS_12 Robust   
 Coef. Std. Err. P>t Coef. Std. Err. P>t Coef. Std. Err. P>t 
group50 0.0313 0.0105 0.003 1.5477 0.5862 0.008 -0.6236 0.6305 0.323 
          
group51 0.0127 0.0085 0.136 0.0693 0.4774 0.885 -0.1262 0.4738 0.790 
group52 0.0223 0.0089 0.012 0.9823 0.4960 0.048 0.1018 0.4951 0.837 
group53 -0.0008 0.0089 0.929 -0.2631 0.4998 0.599 0.6018 0.4955 0.225 
group54 0.0218 0.0094 0.021 0.4638 0.5309 0.382 0.4528 0.5310 0.394 
group55 0.0263 0.0109 0.016 0.5396 0.6320 0.393 1.2578 0.6174 0.042 
group56 0.0154 0.0090 0.087 0.9051 0.4917 0.066 -0.4166 0.4972 0.402 
Constant 1.0999 0.0089 <0.001 75.9777 0.5008 <0.001 61.9277 0.4981 <0.001 
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Table A3.2: Observed and predicted mean SF-6D (MCS-12, PCS-12) (obtained using the health dimension models) 
  
 ICD 
group 
  SF-6D  PCS_12  MCS_12  ICD  
group 
  SF-6D  PCS_12  MCS_12  
N Obs Pred Obs Pred Obs Pred N Obs Pred Obs Pred Obs Pred 
Healthy 117 0.726 0.726 47.42 47.42 49.33 49.33                 
group1 181 0.608 0.608 37.25 37.25 45.61 45.61 group29 940 0.736 0.736 47.25 47.25 48.84 48.84 
group2 100 0.603 0.603 36.08 36.08 45.24 45.24 group30 108 0.760 0.760 50.22 50.22 49.31 49.31 
group3 442 0.771 0.771 48.50 48.50 50.90 50.90 group31 207 0.667 0.667 42.03 42.03 46.37 46.37 
group4 319 0.657 0.657 43.93 43.93 46.48 46.48 group32 121 0.660 0.660 42.82 42.82 45.97 45.97 
group5 149 0.651 0.651 40.98 40.98 47.29 47.29 group33 476 0.774 0.774 50.11 50.11 49.32 49.32 
group6 123 0.709 0.709 45.89 45.89 49.81 49.81 group34 347 0.636 0.636 37.63 37.63 45.57 45.57 
group7 135 0.692 0.692 44.42 44.42 48.07 48.07 group35 175 0.651 0.651 38.84 38.84 47.48 47.48 
group8 272 0.653 0.653 39.21 39.21 47.07 47.07 group36 1978 0.641 0.641 38.45 38.45 48.92 48.92 
group9 163 0.733 0.733 47.63 47.63 49.27 49.27 group37 1574 0.562 0.562 33.36 33.36 45.65 45.65 
group10 1198 0.752 0.752 48.86 48.86 49.64 49.64 group38 752 0.686 0.686 43.15 43.15 48.77 48.77 
group11 163 0.699 0.699 44.25 44.25 48.63 48.63 group39 165 0.616 0.616 37.72 37.72 45.83 45.83 
group12 418 0.692 0.692 43.32 43.32 48.18 48.18 group40 747 0.701 0.701 45.01 45.01 47.74 47.74 
group13 148 0.680 0.680 44.37 44.37 45.62 45.62 group41 220 0.764 0.764 48.58 48.58 49.97 49.97 
group14 316 0.713 0.713 45.59 45.59 48.29 48.29 group42 1636 0.734 0.734 48.51 48.51 48.58 48.58 
group15 156 0.693 0.693 42.28 42.28 48.74 48.74 group43 128 0.687 0.687 45.42 45.42 46.39 46.39 
group16 106 0.723 0.723 47.03 47.03 48.09 48.09 group44 491 0.707 0.707 44.21 44.21 48.50 48.50 
group17 122 0.625 0.625 43.11 43.11 43.14 43.14 group45 438 0.707 0.707 45.10 45.10 48.02 48.02 
group18 130 0.604 0.604 33.45 33.45 47.65 47.65 group46 1756 0.666 0.666 42.43 42.43 46.38 46.38 
group19 271 0.661 0.661 42.81 42.81 45.72 45.72 group47 892 0.603 0.603 40.68 40.68 42.28 42.28 
group20 397 0.703 0.703 44.37 44.37 48.91 48.91 group48 1022 0.684 0.684 42.09 42.09 48.60 48.60 
group21 219 0.603 0.603 36.75 36.75 46.03 46.03 group49 528 0.690 0.690 43.03 43.03 47.69 47.69 
group22 207 0.728 0.728 46.14 46.14 48.87 48.87 group50 234 0.763 0.763 50.93 50.93 47.64 47.64 
group23 349 0.748 0.748 46.51 46.51 49.85 49.85 group51 5845 0.702 0.702 45.15 45.15 47.73 47.73 
group24 224 0.733 0.733 47.78 47.78 48.97 48.97 group52 1317 0.723 0.723 46.88 46.88 48.22 48.22 
group25 209 0.723 0.723 45.92 45.92 48.66 48.66 group53 1549 0.673 0.673 43.17 43.17 48.24 48.24 
group26 224 0.763 0.763 49.39 49.39 49.60 49.60 group54 517 0.732 0.732 46.36 46.36 49.43 49.43 
group27 2297 0.648 0.648 39.74 39.74 47.45 47.45 group55 223 0.686 0.686 42.31 42.31 48.84 48.84 
group28 305 0.634 0.634 39.90 39.90 45.33 45.33 group56 1280 0.777 0.777 52.78 52.78 48.78 48.78 
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Table A3.3: Regression models to predict SF-6D, MCS or PCS scores (using EQ-5D preference scores) 
 SF-6D   MCS   PCS   
  Coef. 95% Conf. Interval P>t Coef. 95% Conf. Interval P>t  Coef 95% Conf. Interval P>t 
Age/10 0.0031 (0.0021 to 0.0041) <0.001 1.0463 (0.9827 to 1.1100) <0.001 -0.8967 (-0.9631 to -0.8304) <0.001 
Female -0.0164 (-0.0189 to -0.0139) <0.001 -0.3638 (-0.5260 to -0.2017) <0.001 -0.5284 (-0.7019 to -0.3549) <0.001 
EQ-5D 0.3664 (0.3630 to 0.3698) <0.001 15.4859 (15.2035 to 15.7683) <0.001 24.6795 (24.4046 to 24.9544) <0.001 
Group01 -0.056 (-0.0786 to -0.0335) <0.001 -1.8756 (-3.4074 to -0.3439) 0.016 -4.6293 (-6.3586 to -2.9001) <0.001 
Group02 -0.064 (-0.0909 to -0.0371) <0.001 -2.2881 (-4.1662 to -0.4099) 0.017 -6.2497 (-8.3223 to -4.1771) <0.001 
Group03 0.0422 (0.0215 to 0.0630) <0.001 0.7621 (-0.5043 to 2.0285) 0.238 1.9065 (0.6092 to 3.2038) 0.004 
Group04 -0.0365 (-0.0578 to -0.0153) 0.001 -2.1675 (-3.5298 to -0.8052) 0.002 -0.7471 (-2.1427 to 0.6485) 0.294 
Group05 -0.0404 (-0.0649 to -0.0160) 0.001 -1.1907 (-2.8014 to 0.4201) 0.147 -3.7135 (-5.3588 to -2.0682) <0.001 
Group06 -0.027 (-0.0544 to 0.0004) 0.054 -0.5358 (-2.1703 to 1.0987) 0.521 -0.7749 (-2.4846 to 0.9347) 0.374 
Group07 -0.0212 (-0.0486 to 0.0062) 0.13 -1.687 (-3.3316 to -0.0424) 0.044 -0.6145 (-2.4859 to 1.2568) 0.52 
Group08 -0.025 (-0.0468 to -0.0032) 0.024 -0.6011 (-2.0180 to 0.8158) 0.406 -4.2651 (-5.7565 to -2.7737) <0.001 
Group09 0.0085 (-0.0159 to 0.0329) 0.494 -0.1541 (-1.6193 to 1.3111) 0.837 0.314 (-1.2387 to 1.8668) 0.692 
Group10 0.027 (0.0076 to 0.0463) 0.006 0.3734 (-0.8213 to 1.5682) 0.54 1.405 (0.1975 to 2.6124) 0.023 
Group11 -0.0102 (-0.0369 to 0.0165) 0.454 -0.2303 (-1.9018 to 1.4412) 0.787 -1.5722 (-3.2694 to 0.1251) 0.069 
Group12 0.0159 (-0.0050 to 0.0368) 0.136 0.922 (-0.4114 to 2.2554) 0.175 -0.5661 (-1.9433 to 0.8111) 0.42 
Group13 -0.005 (-0.0294 to 0.0195) 0.691 -1.7194 (-3.4110 to -0.0278) 0.046 -0.4332 (-2.2122 to 1.3459) 0.633 
Group14 0.0153 (-0.0061 to 0.0368) 0.162 0.0977 (-1.2583 to 1.4537) 0.888 0.1914 (-1.1797 to 1.5624) 0.784 
Group15 0.0087 (-0.0173 to 0.0346) 0.513 1.7551 (0.2130 to 3.2972) 0.026 -2.8307 (-4.5576 to -1.1038) 0.001 
Group16 0.0039 (-0.0240 to 0.0318) 0.785 -0.9688 (-2.7773 to 0.8398) 0.294 0.0216 (-1.7083 to 1.7514) 0.981 
Group17 -0.0214 (-0.0472 to 0.0043) 0.102 -2.6172 (-4.3437 to -0.8907) 0.003 1.0556 (-0.8283 to 2.9394) 0.272 
Group18 -0.0196 (-0.0428 to 0.0036) 0.098 3.0227 (1.3725 to 4.6728) <0.001 -7.5451 (-9.4375 to -5.6528) <0.001 
Group19 0.0013 (-0.0208 to 0.0234) 0.909 -0.6319 (-2.1107 to 0.8469) 0.402 -0.1892 (-1.6382 to 1.2598) 0.798 
Group20 0.0274 (0.0062 to 0.0486) 0.011 1.2966 (-0.0418 to 2.6351) 0.058 0.8216 (-0.5170 to 2.1602) 0.229 
Group21 -0.0068 (-0.0301 to 0.0165) 0.567 1.8191 (0.2587 to 3.3794) 0.022 -2.9989 (-4.6129 to -1.3848) <0.001 
Group22 0.0285 (0.0044 to 0.0525) 0.021 0.3601 (-1.1400 to 1.8603) 0.638 0.9263 (-0.6260 to 2.4786) 0.242 
Group23 0.0408 (0.0193 to 0.0622) <0.001 0.3977 (-0.9356 to 1.7311) 0.559 1.6825 (0.3254 to 3.0396) 0.015 
Group24 0.0044 (-0.0184 to 0.0272) 0.708 -0.9829 (-2.4182 to 0.4524) 0.18 1.1024 (-0.3240 to 2.5288) 0.13 
Group25 0.0127 (-0.0109 to 0.0364) 0.292 -0.1649 (-1.6526 to 1.3228) 0.828 -0.1267 (-1.6343 to 1.3810) 0.869 
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Group26 0.0404 (0.0169 to 0.0638) 0.001 0.5577 (-0.8476 to 1.9630) 0.437 2.1756 (0.7734 to 3.5778) 0.002 
Group27 -0.0255 (-0.0443 to -0.0067) 0.008 -0.4436 (-1.6248 to 0.7376) 0.462 -2.7245 (-3.9150 to -1.5340) <0.001 
Group28 -0.0288 (-0.0506 to -0.0069) 0.01 -1.8314 (-3.2305 to -0.4323) 0.01 -2.4371 (-3.9327 to -0.9416) 0.001 
Group29 0.0281 (0.0085 to 0.0477) 0.005 0.0624 (-1.1484 to 1.2731) 0.92 1.3949 (0.1704 to 2.6194) 0.026 
Group30 0.0209 (-0.0085 to 0.0503) 0.164 0.5718 (-1.1393 to 2.2829) 0.512 0.4844 (-1.0823 to 2.0512) 0.544 
Group31 -0.0071 (-0.0312 to 0.0169) 0.561 -0.9091 (-2.4068 to 0.5886) 0.234 -1.6271 (-3.1546 to -0.0995) 0.037 
Group32 0.0047 (-0.0207 to 0.0301) 0.715 -0.5233 (-2.2326 to 1.1861) 0.549 0.3981 (-1.4079 to 2.2041) 0.666 
Group33 0.0429 (0.0222 to 0.0636) <0.001 0.2889 (-0.9882 to 1.5659) 0.657 1.8934 (0.6344 to 3.1525) 0.003 
Group34 -0.0089 (-0.0306 to 0.0128) 0.419 -0.6311 (-2.0361 to 0.7739) 0.379 -3.887 (-5.3241 to -2.4499) <0.001 
Group35 -0.0121 (-0.0371 to 0.0129) 0.342 0.8199 (-0.7725 to 2.4122) 0.313 -3.9735 (-5.6829 to -2.2640) <0.001 
Group36 0.0051 (-0.0138 to 0.0239) 0.598 3.0384 (1.8512 to 4.2256) <0.001 -2.3949 (-3.5922 to -1.1977) <0.001 
Group37 -0.0107 (-0.0297 to 0.0083) 0.269 2.7012 (1.4925 to 3.9099) <0.001 -3.4941 (-4.7125 to -2.2758) <0.001 
Group38 0.0183 (-0.0017 to 0.0384) 0.072 1.4881 (0.2424 to 2.7337) 0.019 0.2659 (-0.9899 to 1.5216) 0.678 
Group39 0.0063 (-0.0188 to 0.0315) 0.621 1.5956 (-0.0738 to 3.2650) 0.061 -1.9591 (-3.5908 to -0.3274) 0.019 
Group40 0.0139 (-0.0060 to 0.0339) 0.171 0.0747 (-1.1724 to 1.3217) 0.907 0.396 (-0.8654 to 1.6575) 0.538 
Group41 0.0421 (0.0189 to 0.0654) <0.001 0.8709 (-0.5351 to 2.2769) 0.225 2.0181 (0.5461 to 3.4901) 0.007 
Group42 0.0215 (0.0025 to 0.0405) 0.026 -0.061 (-1.2474 to 1.1253) 0.92 1.6068 (0.4180 to 2.7956) 0.008 
Group43 -0.0028 (-0.0297 to 0.0241) 0.839 -1.1611 (-2.8161 to 0.4938) 0.169 0.2262 (-1.4137 to 1.8661) 0.787 
Group44 0.0069 (-0.0138 to 0.0276) 0.516 -0.3042 (-1.5832 to 0.9748) 0.641 -0.5424 (-1.8960 to 0.8112) 0.432 
Group45 0.0127 (-0.0083 to 0.0337) 0.236 -0.0911 (-1.4090 to 1.2268) 0.892 0.1659 (-1.1733 to 1.5051) 0.808 
Group46 0.0008 (-0.0181 to 0.0198) 0.932 -0.5691 (-1.7635 to 0.6253) 0.35 -0.5374 (-1.7395 to 0.6647) 0.381 
Group47 -0.0176 (-0.0371 to 0.0018) 0.076 -2.3566 (-3.6616 to -1.0517) <0.001 0.1523 (-1.1337 to 1.4382) 0.816 
Group48 -0.0008 (-0.0201 to 0.0186) 0.939 0.5948 (-0.6169 to 1.8066) 0.336 -1.8065 (-3.0520 to -0.5610) 0.004 
Group49 0.012 (-0.0085 to 0.0326) 0.252 0.2065 (-1.0814 to 1.4943) 0.753 -0.7034 (-2.0434 to 0.6366) 0.304 
Group50 0.0414 (0.0186 to 0.0642) <0.001 -0.637 (-2.1660 to 0.8919) 0.414 2.7809 (1.3550 to 4.2068) <0.001 
Group51 0.0157 (-0.0028 to 0.0341) 0.096 -0.0071 (-1.1636 to 1.1493) 0.99 0.5806 (-0.5774 to 1.7386) 0.326 
Group52 0.0273 (0.0081 to 0.0465) 0.005 0.3828 (-0.8204 to 1.5860) 0.533 1.4161 (0.2149 to 2.6173) 0.021 
Group53 -0.0117 (-0.0309 to 0.0075) 0.231 1.2996 (0.0958 to 2.5033) 0.034 -1.9972 (-3.2051 to -0.7893) 0.001 
Group54 0.0262 (0.0057 to 0.0467) 0.012 0.5337 (-0.7487 to 1.8161) 0.415 1.1281 (-0.1692 to 2.4253) 0.088 
Group55 0.0218 (-0.0018 to 0.0454) 0.07 2.5512 (1.1129 to 3.9895) 0.001 -1.2728 (-2.7608 to 0.2152) 0.094 
Group56 0.0292 (0.0099 to 0.0485) 0.003 -0.2264 (-1.4300 to 0.9773) 0.712 2.1549 (0.9686 to 3.3412) <0.001 
50 
 
Constant 0.4242 (0.4050 to 0.4435) <0.001 32.0884 (30.8646 to 33.3123) <0.001 31.8314 (30.6103 to 33.0524) <0.001 
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Table A3.4 : Observed (Obs) and predicted mean SF-6D  
ICD 
group N Obs 
Predicted  
using  
Health  
dimensions 
Predicted 
Using 
Preference- 
based index 
ICD  
group N Obs 
Predicted 
using 
Health  
dimensions 
Predicted 
using 
Preference- 
based index 
Healthy 117 0.72617 0.72617 0.72617          
group1 181 0.60767 0.60767 0.60767 group29 940 0.73630 0.73630 0.73630 
group2 100 0.60252 0.60252 0.60252 group30 108 0.76009 0.76009 0.76009 
group3 442 0.77104 0.77104 0.77104 group31 207 0.66738 0.66738 0.66738 
group4 319 0.65680 0.65680 0.65680 group32 121 0.66033 0.66033 0.66033 
group5 149 0.65133 0.65133 0.65133 group33 476 0.77405 0.77405 0.77405 
group6 123 0.70868 0.70868 0.70868 group34 347 0.63570 0.63570 0.63570 
group7 135 0.69237 0.69237 0.69237 group35 175 0.65073 0.65073 0.65073 
group8 272 0.65283 0.65283 0.65283 group36 1978 0.64150 0.64150 0.64150 
group9 163 0.73267 0.73267 0.73267 group37 1574 0.56186 0.56186 0.56186 
group10 1198 0.75245 0.75245 0.75245 group38 752 0.68645 0.68645 0.68645 
group11 163 0.69948 0.69948 0.69948 group39 165 0.61646 0.61646 0.61646 
group12 418 0.69186 0.69186 0.69186 group40 747 0.70066 0.70066 0.70066 
group13 148 0.68018 0.68018 0.68018 group41 220 0.76418 0.76418 0.76418 
group14 316 0.71301 0.71301 0.71301 group42 1636 0.73364 0.73364 0.73364 
group15 156 0.69257 0.69257 0.69257 group43 128 0.68745 0.68745 0.68745 
group16 106 0.72262 0.72262 0.72262 group44 491 0.70674 0.70674 0.70674 
group17 122 0.62499 0.62499 0.62499 group45 438 0.70656 0.70656 0.70656 
group18 130 0.60398 0.60398 0.60398 group46 1756 0.66628 0.66628 0.66628 
group19 271 0.66128 0.66128 0.66128 group47 892 0.60280 0.60280 0.60280 
group20 397 0.70288 0.70288 0.70288 group48 1022 0.68427 0.68427 0.68427 
group21 219 0.60341 0.60341 0.60341 group49 528 0.68991 0.68991 0.68991 
group22 207 0.72844 0.72844 0.72844 group50 234 0.76307 0.76307 0.76307 
group23 349 0.74781 0.74781 0.74781 group51 5845 0.70242 0.70242 0.70242 
group24 224 0.73288 0.73288 0.73288 group52 1317 0.72266 0.72266 0.72266 
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group25 209 0.72327 0.72327 0.72327 group53 1549 0.67344 0.67344 0.67344 
group26 224 0.76251 0.76251 0.76251 group54 517 0.73199 0.73199 0.73199 
group27 2297 0.64800 0.64800 0.64800 group55 223 0.68586 0.68586 0.68586 
group28 305 0.63376 0.63376 0.63376 group56 1280 0.77674 0.77674 0.77674 
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Table A3.5: Observed and predicted mean SF-6D, PCS and MCS values by EQ-5D score 
ICD Group N SF-6D PCS MCS 
EQ-5D < 0.5 
    Observed Predicted Observed Predicted Observed Predicted 
1 38 0.49 0.43 27.81 25.34 39.63 38.27 
2 16 0.55 0.44 30.29 25.79 43.00 38.30 
3 30 0.52 0.52 31.56 31.49 42.86 40.51 
4 32 0.50 0.43 29.45 29.05 39.37 36.82 
5 20 0.48 0.44 27.00 26.86 39.58 38.52 
6 10 0.54 0.52 33.48 33.40 43.84 41.62 
7 11 0.51 0.47 32.56 29.88 38.50 38.52 
8 54 0.50 0.46 26.65 26.30 41.30 39.25 
9 9 0.49 0.47 31.88 29.40 37.87 38.48 
10 93 0.52 0.50 34.76 31.95 39.18 39.33 
11 17 0.50 0.45 28.10 26.93 41.63 38.60 
12 83 0.51 0.47 30.56 28.46 41.08 38.82 
13 29 0.54 0.50 36.25 32.43 38.41 37.99 
14 40 0.50 0.46 30.89 28.37 38.54 37.56 
15 20 0.50 0.46 25.05 26.03 42.60 39.46 
16 8 0.54 0.46 33.95 29.62 36.27 36.87 
17 36 0.53 0.45 35.60 31.07 36.34 36.04 
18 34 0.51 0.45 28.36 22.71 43.03 41.54 
19 64 0.50 0.45 29.68 28.79 40.05 37.12 
20 68 0.51 0.48 30.83 29.44 41.46 39.91 
21 80 0.52 0.46 28.44 26.29 43.75 40.11 
22 29 0.54 0.49 31.94 29.95 42.00 38.80 
23 46 0.49 0.49 28.65 29.58 39.26 39.02 
24 16 0.45 0.47 29.80 30.32 32.12 38.08 
25 23 0.49 0.48 29.21 29.16 37.51 38.28 
26 22 0.51 0.52 35.81 32.41 38.63 39.65 
27 427 0.49 0.44 28.34 25.93 39.34 38.69 
28 65 0.49 0.43 27.73 26.17 37.71 36.96 
29 102 0.50 0.48 31.60 29.90 37.46 38.28 
30 5 0.51 0.45 25.00 27.98 47.82 37.86 
31 44 0.49 0.44 29.34 26.76 36.44 36.93 
32 32 0.49 0.45 31.19 28.17 38.22 37.24 
33 40 0.54 0.52 35.56 32.42 40.05 39.38 
34 84 0.48 0.44 27.33 23.85 37.35 37.46 
35 40 0.51 0.48 28.06 26.92 42.84 40.33 
36 492 0.50 0.45 28.20 25.71 42.66 41.12 
37 705 0.47 0.42 26.28 23.72 40.95 39.66 
38 163 0.50 0.48 30.59 29.03 40.33 39.90 
39 65 0.49 0.46 27.33 26.72 40.90 39.63 
40 122 0.52 0.47 32.37 29.40 39.50 38.24 
41 32 0.52 0.53 36.10 32.39 38.28 40.00 
42 157 0.51 0.49 35.88 32.09 38.32 37.99 
43 18 0.49 0.47 30.07 30.88 39.30 37.40 
44 69 0.50 0.48 28.53 28.96 40.30 38.96 
45 57 0.48 0.46 29.06 28.80 37.44 37.90 
46 367 0.49 0.45 30.14 27.97 38.13 37.46 
47 327 0.49 0.45 32.87 29.93 35.19 35.74 
48 165 0.50 0.47 29.14 27.31 40.50 39.61 
49 104 0.49 0.46 29.82 27.66 37.58 38.17 
50 29 0.55 0.55 42.57 36.08 34.49 38.94 
51 969 0.50 0.47 31.51 29.63 38.57 38.24 
52 209 0.50 0.48 32.16 30.55 39.11 38.19 
53 253 0.51 0.48 32.06 29.82 41.61 40.41 
54 67 0.51 0.50 31.32 30.50 39.60 39.44 
55 46 0.47 0.47 27.01 26.94 41.22 40.03 
56 57 0.53 0.52 41.40 35.67 34.58 37.52 
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ICD Group N SF-6D PCS MCS 
0.5 <= EQ-5D < 0.69 
    Observed Predicted Observed Predicted Observed Predicted 
1 62 0.58 0.61 34.93 37.21 44.6 45.56 
2 32 0.50 0.59 29.66 34.83 40.23 44.80 
3 55 0.60 0.70 37.16 43.72 46.67 47.94 
4 78 0.58 0.63 38.85 41.70 43.13 45.33 
5 34 0.56 0.61 35.76 38.34 43.33 45.83 
6 21 0.56 0.65 38.90 42.05 43.39 47.27 
7 31 0.56 0.65 34.98 41.39 42.06 46.13 
8 64 0.55 0.63 32.61 37.40 43.53 45.97 
9 26 0.57 0.67 39.50 43.21 43.18 46.84 
10 125 0.57 0.68 38.37 43.92 43.18 47.09 
11 24 0.57 0.65 34.51 40.69 44.28 46.63 
12 61 0.58 0.67 35.94 41.13 44.85 47.31 
13 27 0.56 0.64 35.37 41.21 41.04 44.58 
14 52 0.58 0.66 36.68 42.05 43.82 46.51 
15 30 0.56 0.66 34.56 40.11 44.41 47.50 
16 16 0.59 0.67 40.27 43.37 43.66 45.72 
17 28 0.55 0.64 37.89 43.86 43.21 43.85 
18 49 0.58 0.62 30.82 34.89 46.91 48.22 
19 60 0.59 0.66 38.64 42.29 43.19 45.99 
20 65 0.61 0.68 39.22 43.01 46.12 48.16 
21 59 0.57 0.64 34.39 39.02 45.14 47.74 
22 29 0.57 0.69 36.47 43.00 43.36 47.60 
23 40 0.59 0.70 35.12 42.96 44.69 47.93 
24 28 0.60 0.67 37.64 42.90 45.83 46.61 
25 30 0.59 0.67 37.79 42.12 44.96 46.77 
26 15 0.57 0.70 39.36 45.15 40.20 47.39 
27 615 0.57 0.64 35.35 38.95 44.10 46.97 
28 69 0.55 0.63 32.07 39.35 44.31 44.99 
29 125 0.58 0.69 36.82 43.42 45.31 47.11 
30 8 0.53 0.67 34.57 42.62 44.80 46.83 
31 31 0.56 0.65 35.81 40.43 43.06 45.84 
32 13 0.61 0.66 39.61 42.24 44.85 46.71 
33 44 0.59 0.71 38.97 44.93 42.91 46.94 
34 94 0.55 0.64 32.63 37.74 42.95 45.76 
35 39 0.54 0.64 31.90 37.91 44.14 47.09 
36 479 0.58 0.65 35.14 39.05 46.99 49.66 
37 356 0.55 0.64 33.45 38.47 45.76 48.96 
38 140 0.58 0.68 37.83 42.62 45.68 48.56 
39 29 0.56 0.66 34.36 40.03 44.83 47.88 
40 118 0.59 0.67 38.30 42.86 44.04 46.71 
41 18 0.60 0.71 39.42 43.81 45.31 48.31 
42 165 0.58 0.68 38.91 44.53 43.11 46.33 
43 25 0.56 0.65 41.36 42.35 40.30 45.07 
44 86 0.56 0.66 34.21 41.27 43.76 46.66 
45 83 0.59 0.67 36.99 41.92 44.97 46.61 
46 360 0.58 0.66 36.70 41.60 43.60 46.31 
47 166 0.56 0.64 36.69 42.46 42.06 44.05 
48 204 0.58 0.66 35.10 40.02 44.63 47.66 
49 77 0.57 0.67 35.86 41.33 43.59 47.21 
50 17 0.58 0.70 39.33 45.38 43.06 45.92 
51 872 0.58 0.67 37.97 43.08 43.57 46.73 
52 163 0.59 0.68 38.27 43.82 44.26 46.98 
53 289 0.56 0.64 37.06 40.87 43.57 47.31 
54 71 0.58 0.69 36.80 43.33 44.15 47.95 
55 38 0.58 0.67 37.81 41.00 44.50 48.52 
56 36 0.60 0.69 41.50 46.95 42.54 44.95 
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ICD Group N SF-6D PCS MCS 
0.69 <= EQ-5D < 0.79 
    Observed Predicted Observed Predicted Observed Predicted 
1 22 0.62 0.65 36.65 40.16 48.87 47.25 
2 28 0.63 0.63 37.98 38.25 46.87 46.37 
3 75 0.71 0.74 43.98 46.29 50.37 49.81 
4 63 0.64 0.66 43.23 44.03 48.03 46.63 
5 22 0.63 0.65 36.54 40.81 47.93 47.54 
6 20 0.62 0.68 37.33 43.78 50.78 49.22 
7 25 0.68 0.68 43.53 43.77 48.99 47.61 
8 43 0.64 0.67 36.78 40.28 48.92 48.16 
9 24 0.67 0.70 40.48 45.07 51.07 48.53 
10 176 0.70 0.72 44.19 46.37 49.77 48.78 
11 27 0.69 0.69 39.33 43.17 50.49 48.14 
12 72 0.68 0.71 40.91 44.40 50.73 49.15 
13 24 0.66 0.70 41.91 45.10 47.53 46.66 
14 46 0.69 0.71 42.12 44.96 50.17 48.29 
15 35 0.68 0.70 39.95 42.95 49.93 49.05 
16 14 0.65 0.69 39.71 44.93 50.97 46.94 
17 12 0.65 0.67 45.48 46.64 44.32 45.23 
18 25 0.63 0.66 33.22 37.27 51.95 50.37 
19 32 0.66 0.70 41.97 45.27 47.69 47.18 
20 94 0.70 0.72 44.89 45.74 50.18 49.70 
21 31 0.68 0.69 42.61 42.78 50.41 49.25 
22 34 0.69 0.73 43.12 45.70 49.56 48.84 
23 64 0.72 0.74 44.27 45.81 50.62 49.46 
24 37 0.67 0.71 43.67 45.64 48.27 48.12 
25 40 0.66 0.71 41.97 44.77 48.59 48.02 
26 35 0.69 0.74 46.6 47.51 48.48 48.79 
27 458 0.67 0.68 39.22 41.61 51.02 48.77 
28 63 0.66 0.67 40.98 42.13 46.87 46.86 
29 167 0.70 0.72 43.76 46.20 49.74 48.57 
30 10 0.61 0.71 45.19 46.57 42.12 47.37 
31 28 0.65 0.69 37.75 43.43 50.01 47.53 
32 27 0.67 0.70 41.25 45.44 49.51 47.52 
33 47 0.69 0.74 46.02 47.48 47.26 48.10 
34 60 0.70 0.69 38.75 40.67 50.35 47.91 
35 38 0.68 0.69 40.57 41.27 49.78 49.18 
36 568 0.69 0.70 40.71 42.14 52.73 51.25 
37 330 0.66 0.68 39.74 41.37 51.86 50.73 
38 146 0.70 0.72 42.86 45.29 51.76 50.14 
39 32 0.68 0.70 45.21 43.80 48.21 48.82 
40 130 0.68 0.71 43.23 45.45 49.25 48.45 
41 25 0.71 0.75 44.10 47.04 49.28 49.39 
42 264 0.67 0.71 44.50 46.89 48.19 47.77 
43 23 0.64 0.69 43.12 46.06 45.79 46.28 
44 76 0.67 0.70 42.18 43.95 49.52 48.55 
45 69 0.69 0.71 44.21 45.03 49.11 48.32 
46 323 0.67 0.70 41.70 44.37 49.13 47.87 
47 133 0.66 0.68 41.99 45.43 48.60 45.57 
48 217 0.68 0.70 40.66 42.99 50.73 49.29 
49 102 0.69 0.71 40.08 44.08 51.67 48.74 
50 24 0.68 0.73 46.87 48.06 46.64 47.02 
51 1,105 0.68 0.71 43.80 45.65 48.33 48.23 
52 225 0.70 0.72 44.80 46.70 49.30 48.44 
53 389 0.66 0.68 41.17 43.86 50.55 48.78 
54 108 0.71 0.73 44.42 45.96 50.72 49.24 
55 56 0.70 0.72 42.05 44.37 51.53 50.06 
56 90 0.68 0.72 46.47 48.50 46.10 46.30 
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ICD Group N SF-6D PCS MCS 
0.79 <= EQ-5D < 1 
    Observed Predicted Observed Predicted Observed Predicted 
1 38 0.65 0.68 42.71 42.20 47.36 48.98 
2 15 0.69 0.67 41.65 40.44 51.01 47.88 
3 94 0.79 0.77 51.69 48.77 50.26 51.05 
4 75 0.70 0.69 47.76 46.32 47.91 47.79 
5 30 0.68 0.69 45.52 43.95 49.36 48.72 
6 28 0.73 0.72 49.94 47.07 49.66 50.33 
7 31 0.74 0.72 48.95 45.99 50.82 49.03 
8 40 0.72 0.71 46.57 43.13 49.22 49.89 
9 34 0.73 0.74 50.10 47.92 48.11 49.45 
10 265 0.75 0.75 50.58 48.96 49.12 49.75 
11 40 0.70 0.72 48.33 45.9 47.86 49.61 
12 86 0.75 0.75 49.22 47.06 48.90 50.54 
13 26 0.72 0.72 49.97 47.67 47.20 47.28 
14 66 0.72 0.74 49.96 47.82 47.94 49.59 
15 38 0.77 0.74 49.95 45.16 50.86 50.66 
16 25 0.71 0.73 47.98 47.58 46.41 48.65 
17 26 0.68 0.71 50.23 49.29 44.02 46.56 
18 14 0.72 0.71 44.50 40.89 51.29 51.75 
19 56 0.73 0.73 51.50 48.22 46.93 48.32 
20 85 0.78 0.75 49.33 47.63 51.38 51.02 
21 28 0.72 0.72 48.82 45.43 46.91 50.55 
22 41 0.77 0.76 51.43 48.10 49.61 49.97 
23 65 0.79 0.77 51.14 48.37 50.65 50.90 
24 56 0.76 0.75 50.80 48.60 49.57 49.60 
25 34 0.74 0.75 49.75 47.50 48.13 49.69 
26 60 0.80 0.77 51.70 49.86 50.62 50.05 
27 375 0.73 0.72 47.03 44.46 50.38 50.39 
28 55 0.71 0.71 50.06 45.26 47.58 48.41 
29 207 0.78 0.76 51.84 48.73 49.36 49.70 
30 23 0.74 0.75 51.91 49.15 47.11 49.09 
31 46 0.71 0.73 47.74 46.34 47.81 48.62 
32 19 0.72 0.74 50.23 48.64 45.28 49.19 
33 109 0.78 0.77 52.17 49.84 49.21 49.28 
34 45 0.74 0.72 45.17 43.92 49.96 49.06 
35 28 0.75 0.72 47.90 43.57 49.16 50.19 
36 237 0.78 0.74 48.38 45.08 52.30 52.78 
37 106 0.77 0.72 48.83 44.07 52.02 51.95 
38 129 0.79 0.75 50.31 47.07 52.10 51.48 
39 13 0.76 0.73 48.74 46.06 51.63 50.72 
40 170 0.75 0.74 50.16 48.08 49.10 49.38 
41 43 0.80 0.78 49.84 49.64 51.91 50.69 
42 391 0.75 0.74 50.98 49.22 48.68 49.00 
43 25 0.75 0.72 49.79 47.64 48.89 48.03 
44 96 0.75 0.74 49.21 46.46 49.05 49.87 
45 97 0.76 0.74 49.85 47.51 48.83 49.67 
46 326 0.75 0.73 50.07 47.00 48.87 49.03 
47 154 0.69 0.71 51.03 48.77 44.89 46.42 
48 193 0.75 0.74 48.47 45.69 50.91 50.90 
49 96 0.76 0.74 50.47 46.94 49.31 49.78 
50 50 0.73 0.76 52.77 51.74 44.01 47.24 
51 1,219 0.76 0.74 50.49 48.08 49.66 49.41 
52 238 0.75 0.76 51.57 49.30 48.15 49.70 
53 256 0.74 0.72 49.51 46.71 50.11 50.03 
54 99 0.77 0.76 51.55 48.24 50.24 50.70 
55 27 0.79 0.75 49.45 46.75 52.12 51.31 
56 287 0.71 0.75 52.71 51.25 44.92 47.68 
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ICD Group N SF-6D PCS MCS 
for EQ-5D values = 1 
    Observed Predicted Observed Predicted Observed Predicted 
1 21 0.81 0.75 51.95 46.95 52.85 51.22 
2 9 0.82 0.74 54.09 44.87 52.37 51.25 
3 188 0.87 0.84 54.74 53.37 53.96 53.80 
4 71 0.77 0.75 52.62 50.48 50.49 50.59 
5 43 0.79 0.75 50.72 47.65 52.25 51.40 
6 44 0.84 0.78 53.36 50.77 53.89 52.83 
7 37 0.82 0.78 52.68 50.43 53.02 52.03 
8 71 0.83 0.77 52.02 47.79 52.32 51.76 
9 70 0.84 0.80 53.93 52.35 52.95 51.73 
10 539 0.85 0.82 54.39 53.68 53.15 52.23 
11 55 0.82 0.79 52.93 50.48 52.33 52.12 
12 116 0.85 0.81 53.44 51.65 52.90 52.99 
13 42 0.84 0.79 53.68 52.17 51.48 49.95 
14 112 0.85 0.81 53.84 52.34 53.29 52.19 
15 33 0.85 0.80 53.36 50.06 52.70 52.96 
16 43 0.83 0.80 53.82 52.00 51.97 51.10 
17 20 0.81 0.78 53.28 53.60 53.40 49.19 
18 8 0.83 0.77 52.51 45.25 52.02 54.44 
19 59 0.84 0.80 53.49 52.06 52.22 51.51 
20 85 0.85 0.82 53.60 52.58 53.14 53.72 
21 21 0.76 0.78 50.34 49.79 49.53 52.95 
22 74 0.86 0.82 53.96 52.84 53.00 52.72 
23 134 0.88 0.84 54.88 52.83 54.27 53.82 
24 87 0.84 0.80 54.15 52.94 52.99 51.68 
25 82 0.86 0.81 53.93 51.92 53.39 52.14 
26 92 0.86 0.83 53.83 54.55 53.52 52.36 
27 422 0.83 0.78 51.78 48.68 54.05 52.94 
28 53 0.82 0.77 53.16 49.22 51.81 51.00 
29 339 0.86 0.82 54.71 53.48 52.80 52.25 
30 62 0.84 0.81 54.45 53.97 51.99 50.95 
31 58 0.83 0.79 52.50 50.37 52.77 51.46 
32 30 0.82 0.80 53.33 52.64 51.96 51.51 
33 236 0.86 0.84 54.51 54.71 52.54 51.71 
34 64 0.83 0.78 52.14 48.28 52.63 51.26 
35 30 0.85 0.79 51.56 48.43 53.55 52.86 
36 202 0.86 0.80 53.24 49.91 54.10 55.12 
37 77 0.78 0.79 49.09 48.88 52.68 54.65 
38 174 0.86 0.82 54.12 52.09 54.18 54.09 
39 26 0.85 0.80 52.73 51.03 53.46 52.94 
40 207 0.84 0.81 53.18 52.65 52.65 52.15 
41 102 0.87 0.85 54.67 54.42 53.81 53.23 
42 659 0.84 0.81 54.07 53.65 52.49 51.74 
43 37 0.85 0.79 54.11 52.66 52.63 50.61 
44 164 0.86 0.81 54.08 50.98 53.63 52.64 
45 132 0.85 0.81 54.11 52.42 53.36 51.93 
46 380 0.84 0.80 53.78 51.61 52.53 51.53 
47 112 0.82 0.77 53.63 52.69 52.21 49.16 
48 243 0.85 0.80 52.96 50.20 53.70 53.05 
49 149 0.85 0.81 53.18 51.39 53.09 52.51 
50 114 0.88 0.83 54.84 55.79 53.46 50.40 
51 1,680 0.85 0.81 53.77 52.73 53.38 52.18 
52 482 0.86 0.82 54.84 53.89 53.04 52.15 
53 362 0.84 0.79 53.47 51.10 52.82 52.62 
54 172 0.87 0.83 54.40 52.96 54.15 53.30 
55 56 0.87 0.82 54.74 51.62 53.79 53.89 
56 810 0.84 0.81 54.80 55.26 51.72 50.40 
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Figure A3.1 Observed and predicted values against EQ-5D value 
 
SF-6D; average observed vs expected by EQ-5D value 
 
 
 
SF-6D; average observed vs expected by broad EQ-5D 
value 
 
PCS; average observed vs expected by   EQ-5D value 
 
 
PCS; average observed vs expected by broad EQ-5D 
value 
 
MCS; average observed vs expected by EQ-5D value 
 
 
MCS; average observed vs expected by broad EQ-5D 
value 
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Table A3.6:  Observed and predicted probability of being Off work sick 
SF-6D 
Groups 
SF-6D Range N Observed Predicted using 
 SF-6D 
Predicted using 
 MCS & PCS 
Group 1 0.345 to 0.45 90 0.2889 0.3674 0.1856 
Group 2 0.451 to 0.548 459 0.1874 0.1561 0.1148 
Group 3 0.551 to 0.65 2,067 0.0672 0.0580 0.0379 
Group 4 0.651 to 0.699 2,169 0.0175 0.0297 0.0199 
Group 5 0.701 to 0.749 2,626 0.0091 0.0156 0.0130 
Group 6 0.751 to 0.797 1,533 0.0157 0.0084 0.0114 
Group 7 0.800 to 0.846 1,864 0.0075 0.0057 0.0107 
Group 8 0.856 to 0.899 5,115 0.0039 0.0032 0.0094 
Group 9 0.922 to 0.922 7,580 0.0011 0.0017 0.0079 
Group 10 0.934 to 1 2,030 0.0025 0.0008 0.0066 
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Table A3.7: Observed and predicted mean number of days off work by ICD categories 
ICD categories Observed Tobit Two-part model Truncated negative binomial Negative binomial 
1 26.9 27.5 26.5 26.6 17.4 
2 28.8 28.9 28.8 28.5 16.2 
3 10.4 12.8 9.6 9.7 2.7 
4 24.8 25.8 24.5 24.4 17.0 
5 25.2 26.1 24.9 24.8 17.5 
6 24.8 25.6 24.4 24.5 17.7 
7 21.7 22.6 21.2 21.4 7.5 
8 23.3 24.4 22.9 22.8 12.1 
9 17.1 19.2 16.6 16.2 9.4 
10 16.8 18.2 16.2 16.3 6.3 
11 18.2 19.6 17.5 18.0 7.8 
12 12.6 14.3 11.8 12.1 4.3 
13 16.6 18.3 15.7 15.5 8.6 
14 12.3 13.4 11.6 11.7 3.4 
15 12.7 14.8 11.9 12.1 4.7 
16 18.0 19.5 17.2 17.5 9.9 
17 20.2 22.0 19.7 19.7 8.1 
18 19.8 20.7 19.1 19.4 8.2 
19 15.2 16.6 14.4 14.8 6.4 
20 15.8 17.3 15.0 15.3 6.8 
21 23.6 25.0 23.2 23.2 12.6 
22 13.9 16.1 13.1 13.7 3.2 
23 12.3 13.7 11.2 11.6 3.0 
24 20.1 20.9 19.4 19.5 7.7 
25 16.8 17.8 15.9 15.9 6.8 
26 14.5 16.7 13.6 13.7 6.0 
27 23.9 25.3 23.5 23.4 10.7 
28 25.2 26.2 24.9 24.8 15.3 
29 14.0 15.6 13.1 13.4 4.8 
30 6.1 9.9 .
* 
5.4 1.2 
31 16.4 17.2 15.6 15.8 7.9 
32 17.4 19.3 16.7 16.2 8.5 
33 11.2 13.6 10.2 10.5 3.9 
34 14.4 15.8 13.5 13.6 5.2 
35 21.6 23.1 21.1 21.1 10.5 
36 20.9 22.0 20.3 20.3 10.4 
37 21.5 22.7 20.9 21.0 11.2 
38 19.5 20.7 18.9 19.0 7.9 
39 20.2 21.7 19.6 19.7 10.5 
40 12.2 14.3 11.3 11.4 4.8 
41 14.6 16.6 13.6 13.7 4.2 
42 13.9 15.8 13.1 13.2 6.8 
43 16.8 18.5 16.1 16.2 7.4 
44 22.2 23.8 21.8 21.7 7.7 
45 16.8 18.7 16.2 16.3 6.3 
46 15.4 17.2 14.7 14.8 6.3 
47 19.9 21.4 19.3 19.4 9.7 
48 20.2 21.7 19.7 19.7 8.8 
49 13.7 15.4 12.8 13.0 5.1 
50 8.8 11.4 7.8 8.1 3.7 
51 14.5 16.1 13.6 13.9 5.7 
52 13.3 14.9 12.4 12.8 4.6 
53 20.4 21.6 19.8 20.0 13.8 
54 10.6 13.0 9.6 9.9 2.9 
55 20.5 21.8 20.0 19.7 8.1 
56 11.2 13.3 10.3 10.6 4.4 
Healthy 19.8 21.1 19.2 19.3 8.1 
Total 17.6 19.2 17.0 17.1 8.2 
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Table A3.8:  Truncated negative binomial model used to predict the number of days off work 
 
Daysoff NO_zero Coef. 
Robust 
Std. Err. z P>z 
[95% Conf. 
Interval] 
group01 0.225 0.100 2.25 0.025 0.029 0.421 
group02 0.303 0.098 3.1 0.002 0.111 0.495 
group03 -0.739 0.153 -4.82 0.000 -1.039 -0.438 
group04 0.204 0.098 2.08 0.037 0.012 0.396 
group05 0.220 0.102 2.15 0.032 0.019 0.420 
group06 0.135 0.106 1.28 0.202 -0.072 0.342 
group07 0.015 0.129 0.11 0.910 -0.238 0.267 
group08 0.128 0.113 1.13 0.257 -0.093 0.348 
group09 -0.166 0.131 -1.27 0.205 -0.423 0.091 
group10 -0.170 0.103 -1.66 0.097 -0.371 0.031 
group11 -0.088 0.142 -0.62 0.534 -0.366 0.190 
group12 -0.471 0.144 -3.28 0.001 -0.752 -0.189 
group13 -0.190 0.162 -1.17 0.242 -0.508 0.128 
group14 -0.476 0.168 -2.83 0.005 -0.805 -0.146 
group15 -0.424 0.218 -1.95 0.052 -0.852 0.003 
group16 -0.091 0.132 -0.69 0.490 -0.350 0.167 
group17 0.012 0.160 0.08 0.938 -0.301 0.325 
group18 0.031 0.140 0.22 0.825 -0.243 0.306 
group19 -0.278 0.142 -1.96 0.050 -0.556 0.000 
group20 -0.261 0.115 -2.27 0.023 -0.486 -0.036 
group21 0.216 0.109 1.97 0.049 0.001 0.430 
group22 -0.366 0.186 -1.97 0.049 -0.731 -0.002 
group23 -0.601 0.144 -4.18 0.000 -0.883 -0.319 
group24 -0.032 0.117 -0.27 0.787 -0.261 0.198 
group25 -0.210 0.136 -1.54 0.123 -0.476 0.057 
group26 -0.336 0.142 -2.36 0.018 -0.615 -0.057 
group27 0.093 0.097 0.96 0.335 -0.096 0.282 
group28 0.193 0.101 1.91 0.056 -0.005 0.390 
group29 -0.402 0.109 -3.68 0.000 -0.615 -0.188 
group30 -1.176 0.231 -5.09 0.000 -1.629 -0.723 
group31 -0.202 0.139 -1.45 0.146 -0.473 0.070 
group32 -0.219 0.161 -1.36 0.174 -0.534 0.096 
group33 -0.570 0.133 -4.29 0.000 -0.830 -0.309 
group34 -0.338 0.150 -2.25 0.025 -0.633 -0.043 
group35 0.080 0.123 0.65 0.515 -0.161 0.322 
group36 0.017 0.096 0.17 0.863 -0.172 0.205 
group37 0.085 0.097 0.88 0.380 -0.105 0.276 
group38 -0.069 0.103 -0.67 0.500 -0.271 0.132 
group39 0.021 0.128 0.17 0.868 -0.230 0.273 
group40 -0.537 0.121 -4.45 0.000 -0.773 -0.300 
group41 -0.396 0.162 -2.45 0.014 -0.713 -0.080 
group42 -0.342 0.101 -3.39 0.001 -0.539 -0.144 
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Table A3.8: Truncated negative binomial model contd 
 
Daysoff NO_zero Coef. Robust Std. Err. z P>z [95% Conf. Interval] 
group43 -0.140 0.162 -0.87 0.386 -0.457 0.177 
group44 0.069 0.107 0.64 0.521 -0.142 0.279 
group45 -0.166 0.120 -1.38 0.169 -0.402 0.070 
group46 -0.284 0.103 -2.76 0.006 -0.487 -0.082 
group47 0.021 0.102 0.2 0.841 -0.180 0.221 
group48 -0.029 0.101 -0.29 0.775 -0.226 0.169 
group49 -0.429 0.125 -3.44 0.001 -0.674 -0.185 
group50 -0.803 0.185 -4.34 0.000 -1.166 -0.441 
group51 -0.333 0.097 -3.45 0.001 -0.522 -0.144 
group52 -0.404 0.111 -3.65 0.000 -0.621 -0.187 
group53 0.056 0.097 0.58 0.562 -0.133 0.245 
group54 -0.712 0.141 -5.06 0.000 -0.988 -0.436 
group55 0.031 0.123 0.25 0.802 -0.211 0.272 
group56 -0.481 0.109 -4.4 0.000 -0.695 -0.267 
Age/10 0.082 0.008 10.43 0.000 0.067 0.098 
female -0.044 0.018 -2.49 0.013 -0.079 -0.009 
Constant 2.617 0.102 25.61 0.000 2.417 2.818 
       /lnalpha -0.269 0.022 
  
-0.312 -0.226 
alpha 0.764 0.017 
  
0.732 0.798 
Observations 10964 
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Table A3.9: Comparison of productivity estimates 
All results are for 40-year old males. The values for this work are for ICD-10 group 1. 
EQ-5D  
Health state 
Krol* This work; SF-
6D 
This work; PCS 
& MCS 
2,3,1,3,3 11% 50% 45% 
3,3,1,2,1 17% 77% 61% 
2,3,1,2,1 56% 80% 72% 
2,1,3,1,1 51% 77% 72% 
2,2,1,1,1 81% 86% 83% 
1,1,1,1,1 89% 89% 89% 
 
